Evidence & Sources
Every study, guideline, report, and community source cited across the site — and where each is used.
Peer-reviewed studies
- Delayed gastric emptying in an Indonesian population with reflux esophagitis (external link)
Acta Medica Indonesiana, 2011
Cited in Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis (external link)
Addiction Science & Clinical Practice
Cited in Alcohol on a GLP-1: cravings, tolerance, and what actually changes
- Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom (external link)
Advances in Therapy, 2023
Cited in GLP-1 microdosing: what it means, why people do it, and what the evidence actually says
- Psychosocial Outcomes and Aesthetic Expectations in Female Patients Undergoing Body Contouring After GLP-1-Induced Weight Loss: A Prospective Pilot Comparative Study with Post-Bariatric Patients (external link)
Aesthetic Plastic Surgery
Cited in Body-image lag after weight loss vs. body dysmorphia: how to tell the difference
- 11-beta-hydroxysteroid dehydrogenase type 1 (HSD11B1) gene expression in muscle is linked to reduced skeletal muscle index in sarcopenic patients (external link)
Aging Clinical and Experimental Research
Cited in Cortisol, stress, and weight on a GLP-1: what the connection really is
- The effects of calorie restriction, intermittent fasting and vegetarian diets on bone health (external link)
Aging Clinical and Experimental Research, 2019
Cited in Supplements on a GLP-1 journey: what actually helps, and why food comes first
- Psyllium is superior to docusate sodium for treatment of chronic constipation (external link)
Alimentary Pharmacology & Therapeutics, 1998
Cited in Supplements on a GLP-1 journey: what actually helps, and why food comes first, Fiber on a GLP-1: how much you need, which type, and powder vs. capsules
- Gastrointestinal complications of diabetes (external link)
American Family Physician
- The Efficacy and Safety of GLP-1 RAs in the Modification of Cardiovascular Morbidity in Patients with Obesity Without Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials Involving 32,884 Patients (external link)
American Journal of Cardiovascular Drugs, 2025
Cited in GI side effects on a GLP-1: nausea, vomiting, diarrhea, and constipation, Constipation on a GLP-1: why it happens and how to manage it
- A new predictive equation for resting energy expenditure in healthy individuals (external link)
American Journal of Clinical Nutrition, 1990
Cited in Do TDEE calculators still work after big weight loss on a GLP-1?
- Effect of exercise intensity on abdominal fat loss during calorie restriction in overweight and obese postmenopausal women (external link)
American Journal of Clinical Nutrition, 2009
Cited in What a calorie deficit is, and how to find a healthy one for yourself on a GLP-1
- The role of protein in weight loss and maintenance (external link)
American Journal of Clinical Nutrition, 2015
Cited in Why are protein, fat, and carbohydrates important?, GLP-1 myths vs. facts: what the media and social feeds get wrong, High-protein meals and snacks when your appetite is low on a GLP-1, Cronometer, Supplements on a GLP-1 journey: what actually helps, and why food comes first, Protein quality: how to spot it on a nutrition label, and why it matters for muscle, "Your body can only use 30g of protein per meal": what the research actually says
- Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated With Lower Complications in Patients With Type 2 Diabetes Who Develop Acute Pancreatitis: A Multicenter Analysis (external link)
American Journal of Gastroenterology, 2025
- Association Between ADHD and Obesity: A Systematic Review and Meta-Analysis (external link)
American Journal of Psychiatry
Cited in GLP-1 medications and ADHD: what to know if you have both
- Efficacy of undenatured collagen in knee osteoarthritis: review of the literature with limited meta-analysis (external link)
American Journal of Translational Research, 2023
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Effects of GLP-1 receptor agonists on testicular dysfunction: A systematic review and meta-analysis (external link)
Andrology
Cited in How GLP-1 medications affect men vs. women: what the sex differences actually are, HRT for men (testosterone) and GLP-1 medications: what the connection really is, Hormone replacement therapy (HRT) and GLP-1 medications: an overview, Men's health on a GLP-1: testosterone, fertility, muscle, and the things worth watching
- Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite (external link)
Annals of Internal Medicine
Cited in Sleep quality on a GLP-1: why it matters, what changes, and the sleep apnea connection
- Insufficient sleep undermines dietary efforts to reduce adiposity (external link)
Annals of Internal Medicine
Cited in Sleep quality on a GLP-1: why it matters, what changes, and the sleep apnea connection
- Comparative Gastrointestinal Safety of Dulaglutide, Semaglutide, and Tirzepatide in Adults With Type 2 Diabetes (external link)
Annals of Internal Medicine, 2025
Cited in Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes: A Systematic Review of Randomized Controlled Trials (external link)
Annals of Internal Medicine, 2025
Cited in Managing nausea on a GLP-1: practical strategies, GLP-1 side effect timeline: what to expect at each stage, Constipation on a GLP-1: why it happens and how to manage it, GI side effects on a GLP-1: nausea, vomiting, diarrhea, and constipation
- Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis (external link)
Annals of Internal Medicine, 2026
Cited in A new pancreas study on GLP-1 drugs: what it actually shows
- A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care (external link)
Applied Physiology, Nutrition, and Metabolism, 2008
Cited in Does loose skin throw off your DXA, BIA, or Seca body-composition results?
- Improvement of activity-related knee joint discomfort following supplementation of specific collagen peptides (external link)
Applied Physiology, Nutrition, and Metabolism, 2017
Cited in Joint pain on a GLP-1: why it usually gets better, why it sometimes gets worse first, Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies (external link)
Archives of General Psychiatry, 2010
Cited in GLP-1 medications and depression: what the evidence shows, and what to watch
- Effect of thigh strength on incident radiographic and symptomatic knee osteoarthritis in a longitudinal cohort (external link)
Arthritis & Rheumatism, 2009
Cited in Joint pain on a GLP-1: why it usually gets better, why it sometimes gets worse first
- Efficacy and mechanisms of change in exposure-based and cognitive stand-alone body image interventions in women with overweight and obesity (external link)
Behaviour Research and Therapy
Cited in Body-image lag after weight loss vs. body dysmorphia: how to tell the difference
- Decoding the hallmarks of GLP-1RA weight-loss super-responders (external link)
Biology Methods and Protocols
Cited in GLP-1 super-responders (and non-responders): why weight loss varies so much
- Med14 phosphorylation shapes genomic response to GLP-1 Agonist (preprint) (external link)
bioRxiv (preprint), 2025
Cited in A new pancreas study on GLP-1 drugs: what it actually shows
- Semaglutide-associated worsening of atypical anorexia nervosa in an adolescent girl: case report (external link)
BJPsych Open, 2025
Cited in Anxiety around eating or body image emerging during GLP-1 treatment
- Differential effects of GLP-1 receptor agonists on diabetic osteopathy in type 2 diabetes: a patient-stratified network meta-analysis (external link)
BMC Musculoskeletal Disorders
Cited in Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps
- The safety and efficacy of liraglutide combined with metformin in clinical treatment of polycystic ovary syndrome patients: a meta-analysis (external link)
BMC Women's Health
Cited in Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching
- Weight regain after cessation of medication for weight management: systematic review and meta-analysis (external link)
BMJ
Cited in Stretching your GLP-1 dose past 7 days: what drug levels and early studies actually show, Stopping a GLP-1: tapering, weight regain, and restarting safely
- Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study (external link)
BMJ, 2024
Cited in The thyroid C-cell tumor warning: what it means and who it applies to, GLP-1 myths vs. facts: what the media and social feeds get wrong
- Weight stigma, policy initiatives, and harnessing social media to elevate activism (external link)
Body Image
Cited in "Taking a GLP-1 is cheating": where the myth comes from, and what the evidence says
- Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review (external link)
Brain and Behavior, 2025
Cited in GLP-1 medications and anxiety: what the evidence shows, and what to watch, Mood changes and anhedonia on a GLP-1: what the research shows
- GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach (external link)
Brain Sciences
Cited in GLP-1 medications and anxiety: what the evidence shows, and what to watch
- Perioperative management of long-acting GLP-1 receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration (external link)
British Journal of Anaesthesia, 2024
Cited in Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- Impact of gastric emptying on the pharmacokinetics of ethanol as influenced by cisapride (external link)
British Journal of Clinical Pharmacology
Cited in Alcohol on a GLP-1: cravings, tolerance, and what actually changes
- Values for digestible indispensable amino acid scores (DIAAS) for some dairy and plant proteins may better describe protein quality than PDCAAS (external link)
British Journal of Nutrition
Cited in Protein quality: how to spot it on a nutrition label, and why it matters for muscle
- The efficacy of Phaseolus vulgaris as a weight-loss supplement: a systematic review and meta-analysis of randomised clinical trials (external link)
British Journal of Nutrition
Cited in Cortisol, stress, and weight on a GLP-1: what the connection really is
- Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions (external link)
British Journal of Pharmacology, 2026
Cited in Why strength training matters on a GLP-1, How to find a personal trainer when you're on a GLP-1
- A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults (external link)
British Journal of Sports Medicine
Cited in High-protein meals and snacks when your appetite is low on a GLP-1, A beginner's resistance-training plan on a GLP-1: sets, reps, and progression
- Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases: a systematic review and meta-analysis of cohort studies (external link)
British Journal of Sports Medicine, 2022
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Do the associations of daily steps with mortality and incident cardiovascular disease differ by sedentary time levels? A device-based cohort study (external link)
British Journal of Sports Medicine, 2024
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Glucagon-like Peptide-1 Receptor Agonist Use and Pancreatic Cancer Risk in Patients with Chronic Pancreatitis (external link)
Cancers (Basel), 2026
Cited in A new pancreas study on GLP-1 drugs: what it actually shows
- Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study (external link)
Cardiovascular Drugs and Therapy, 2024
Cited in Hair loss on a GLP-1: what the evidence actually shows
- Poorly Controlled Type 3c Diabetes due to Use of Veterinarian Insulin Syringes (external link)
Case Reports in Endocrinology, 2019 — via PubMed
Cited in Reading an insulin syringe: units, mL, and mg for compounded GLP-1 doses
- Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation (external link)
Cell Metabolism
Cited in What a calorie deficit is, and how to find a healthy one for yourself on a GLP-1, Do TDEE calculators still work after big weight loss on a GLP-1?, Why are protein, fat, and carbohydrates important?, TDEE Calculator
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 (external link)
Cell Metabolism, 2018
- The anabolic response to protein ingestion during recovery from exercise has no upper limit in magnitude and duration in vivo in humans (external link)
Cell Reports Medicine
Cited in "Your body can only use 30g of protein per meal": what the research actually says
- Beyond Diabetes: Semaglutide's Role in Modulating Mood Disorders through Neuroinflammation Pathways (external link)
Cellular and Molecular Neurobiology
Cited in GLP-1 medications and anxiety: what the evidence shows, and what to watch
- Nutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists (external link)
Childhood Obesity, 2026
- Acute Systemic Complications Following High-Dose Semaglutide Reinitiation in an Elderly Patient (external link)
Clinical Case Reports, 2026
Cited in Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration
- Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome (external link)
Clinical Endocrinology
Cited in Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching
- Psychiatric and psychological adverse effects associated with dulaglutide, semaglutide, and liraglutide: a VigiBase study (external link)
Clinical Nutrition
Cited in GLP-1s and a history of disordered eating: what the evidence says about safety, GLP-1 medications and depression: what the evidence shows, and what to watch, GLP-1 medications and anxiety: what the evidence shows, and what to watch
- Precision, least significant change and validity of body composition estimates from bioelectrical impedance analysis, 3D-optical scanning, and dual X-ray absorptiometry (external link)
Clinical Nutrition ESPEN, 2026
Cited in Reading your DXA results over time: tracking fat vs. lean mass on a GLP-1
- Medical nutrition in the glucagon-like peptide-1 (GLP-1) era: Protein strategies, micronutrient monitoring, and lean mass preservation (external link)
Clinical Nutrition ESPEN, 2026
Cited in Why are protein, fat, and carbohydrates important?, Micronutrient gaps on a GLP-1: a labs-first guide
- Resistance training during a 12-week protein supplemented VLCD treatment enhances weight-loss outcomes in obese patients (external link)
Clinical Nutrition, 2018
Cited in A beginner's resistance-training plan on a GLP-1: sets, reps, and progression
- The Role of the Dietitian in Weight Management of Adults With Obesity Without Diabetes Using GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of RCTs (external link)
Clinical Obesity, 2025
Cited in Nutritionist vs. dietitian: what's the difference, and who to see on a GLP-1
- Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials (external link)
Clinical Pharmacokinetics, 2021
Cited in Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
- Comparison of the Discovery A and Stratos DR densitometers for assessing whole-body and regional bone mineral density and body composition (external link)
Clinical Physiology and Functional Imaging, 2023
Cited in Reading your DXA results over time: tracking fat vs. lean mass on a GLP-1
- Effect of Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) on Neuropsychiatric Outcomes: A Systematic Review and Meta-Analysis (external link)
Clinical Therapeutics
Cited in GLP-1s and a history of disordered eating: what the evidence says about safety
- Conservative, physical and surgical interventions for managing faecal incontinence and constipation in adults with central neurological diseases (external link)
Cochrane Database of Systematic Reviews
Cited in Fiber on a GLP-1: how much you need, which type, and powder vs. capsules
- Acute Small Bowel Obstruction Induced by Tirzepatide (Mounjaro) (external link)
Cureus
- Severe Gastrointestinal Intolerance After Resuming Maintenance-Dose Semaglutide Following Ramadan-Related Treatment Interruption: A Case Report (external link)
Cureus
Cited in Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration, Stretching your GLP-1 dose past 7 days: what drug levels and early studies actually show
- The Role of Exenatide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, in Idiopathic Intracranial Hypertension and Polycystic Ovary Syndrome: A Case Report (external link)
Cureus
Cited in Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching
- Telogen Effluvium: A Review of the Literature (external link)
Cureus, 2020
Cited in Hair loss on a GLP-1: what the evidence actually shows, GLP-1 side effect timeline: what to expect at each stage
- Assessing the Renal Outcomes of Semaglutide in Diabetic Kidney Disease: A Systematic Review (external link)
Cureus, 2024
- Cosmetic Procedures After Massive Weight Loss Surgery: A Guide for Prospective Patients (external link)
Cureus, 2024
Cited in Loose skin after GLP-1 weight loss: what actually helps and what's hype
- Efficacy of Probiotics in the Management of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis (external link)
Cureus, 2024
Cited in Physician's Choice Digestive Enzymes & 60 Billion Probiotic: are they worth it on a GLP-1?
- Unmasking Semaglutide-Induced Gastroparesis: The Dangers of Rapid Dose Escalation in a Diabetic Patient (external link)
Cureus, 2025
Cited in Electrolytes on a GLP-1: when plain water isn't enough, How GLP-1 titration schedules work, Why hydration matters on a GLP-1: effects on weight loss and side effects, Kidney injury risk from dehydration on a GLP-1
- Pharmacological Treatment of Body Dysmorphic Disorder (external link)
Current Neuropharmacology
Cited in Body-image lag after weight loss vs. body dysmorphia: how to tell the difference
- Health Consequences of Weight Stigma: Implications for Obesity Prevention and Treatment (external link)
Current Obesity Reports
Cited in "Taking a GLP-1 is cheating": where the myth comes from, and what the evidence says
- Estimating Cardiovascular Benefits of Tirzepatide in Sleep Apnea and Obesity: Insight from the SURMOUNT-OSA Trials (external link)
Current Obesity Reports, 2024
Cited in Zepbound
- Gut hormones and appetite regulation (external link)
Current Opinion in Endocrinology, Diabetes and Obesity, 2024
Cited in Can you boost GLP-1 naturally? How food and lifestyle compare to the medications
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (external link)
Current Reviews in Musculoskeletal Medicine
Cited in "Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you
- Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of "Ozempic Face" (external link)
Dermatology and Therapy, 2026
Cited in GLP-1 face: prevention, skincare, and what it actually signals, GLP-1 myths vs. facts: what the media and social feeds get wrong, Loose skin after GLP-1 weight loss: what actually helps and what's hype
- Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system (external link)
Diabetes & Metabolism, 2011
Cited in Can you boost GLP-1 naturally? How food and lifestyle compare to the medications
- PIONEER 1: Oral Semaglutide Monotherapy vs Placebo in Type 2 Diabetes (external link)
Diabetes Care, 2019
Cited in Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
- GLP-1 Receptor Agonists and the Risk of Thyroid Cancer (external link)
Diabetes Care, 2023
Cited in The thyroid C-cell tumor warning: what it means and who it applies to, GLP-1 myths vs. facts: what the media and social feeds get wrong
- Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? (external link)
Diabetes Care, 2024
Cited in Common mistakes people make on GLP-1 medications — and how to avoid them, Protein quality: how to spot it on a nutrition label, and why it matters for muscle, Body-image lag after weight loss vs. body dysmorphia: how to tell the difference, How to find a personal trainer when you're on a GLP-1, A beginner's resistance-training plan on a GLP-1: sets, reps, and progression, Why strength training matters on a GLP-1, Reading your DXA results over time: tracking fat vs. lean mass on a GLP-1, NASM (National Academy of Sports Medicine)
- Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease (external link)
Diabetes Therapy, 2020
Cited in Why hydration matters on a GLP-1: effects on weight loss and side effects
- Effect of Various Dosing Conditions on the Pharmacokinetics of Oral Semaglutide (external link)
Diabetes Therapy, 2021
Cited in Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
- Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans (external link)
Diabetes, 2011
Cited in Do GLP-1 receptors "burn out"? What long-term use actually does
- Gastrointestinal Adverse Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists: A Comprehensive Update in Diabetic and Obese Populations (external link)
Diabetes, Metabolic Syndrome and Obesity, 2026
- Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis (external link)
Diabetes, Obesity & Metabolism
Cited in Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching
- Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study (external link)
Diabetes, Obesity & Metabolism
Cited in How GLP-1 medications affect men vs. women: what the sex differences actually are, Getting mental health support while on a GLP-1: finding a therapist and the challenges to name, Men's health on a GLP-1: testosterone, fertility, muscle, and the things worth watching, Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching
- The effects of anti-obesity medications on bone metabolism: A critical appraisal (external link)
Diabetes, Obesity & Metabolism
Cited in Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps
- Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss (external link)
Diabetes, Obesity & Metabolism, 2021
Cited in How GLP-1 titration schedules work, Constipation on a GLP-1: why it happens and how to manage it, Common GLP-1 side effects and how to manage them, GI side effects on a GLP-1: nausea, vomiting, diarrhea, and constipation, GLP-1 side effect timeline: what to expect at each stage, What is suppression, satiation, and satiety on a GLP-1?, Talking to your doctor about side effects that aren't improving, Managing nausea on a GLP-1: practical strategies
- Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies (external link)
Diabetes, Obesity & Metabolism, 2025
Cited in GLP-1 super-responders (and non-responders): why weight loss varies so much, The cardiovascular benefits of GLP-1 medications
- Association of GLP-1 Receptor Agonist Use With Safety Outcomes in Individuals With Opioid Use Disorder: A Target Trial Emulation (external link)
Diabetes, Obesity & Metabolism, 2026
Cited in Anxiety around eating or body image emerging during GLP-1 treatment
- Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide (external link)
Diabetes, Obesity and Metabolism
Cited in Stopping a GLP-1: tapering, weight regain, and restarting safely
- Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity (external link)
Diabetes, Obesity and Metabolism, 2018
Cited in Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- The novel dual GIP and GLP-1 receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists (external link)
Diabetes, Obesity and Metabolism, 2020
Cited in Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity (external link)
Diabetes, Obesity and Metabolism, 2021
Cited in Calories in, calories out: the energy balance behind a calorie deficit on a GLP-1, Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- Weight regain after withdrawal of semaglutide (STEP 1 trial extension) (external link)
Diabetes, Obesity and Metabolism, 2022
Cited in Tapering vs. staying on a maintenance dose for long-term use, Talking to friends and family who are skeptical about GLP-1 use, Talking to your doctor about stopping or tapering off treatment, Common mistakes people make on GLP-1 medications — and how to avoid them, Stopping a GLP-1: tapering, weight regain, and restarting safely, GLP-1 myths vs. facts: what the media and social feeds get wrong, What to realistically expect on a GLP-1, Do GLP-1 receptors "burn out"? What long-term use actually does
- Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial (external link)
Diabetes, Obesity and Metabolism, 2024
Cited in Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- Association of patient characteristics and insurance type with anti-obesity medications prescribing and fills (external link)
Diabetes, Obesity and Metabolism, 2024
- Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials (external link)
Diabetes, Obesity and Metabolism, 2025
- Comparative safety of glucose-lowering medications on depression in adults with type 2 diabetes (external link)
Diabetes, Obesity and Metabolism, 2026
Cited in GLP-1 medications and depression: what the evidence shows, and what to watch
- GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study (external link)
Diabetes, Obesity and Metabolism, 2026
Cited in GLP-1 medications and depression: what the evidence shows, and what to watch
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Psychiatric Disorders: A Systematic Review and Meta-Analysis of Randomised Controlled Trials (external link)
Diabetes, Obesity and Metabolism, 2026
Cited in GLP-1 medications and anxiety: what the evidence shows, and what to watch, GLP-1 medications and depression: what the evidence shows, and what to watch
- Risk of Psychiatric Worsening With GLP-1 Receptor Agonist Use in Patients With Type 2 Diabetes and Treated Depression (external link)
Diabetes, Obesity and Metabolism, 2026
Cited in GLP-1 medications and depression: what the evidence shows, and what to watch
- Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials (external link)
Diabetes, Obesity and Metabolism, 2026
Cited in GLP-1 myths vs. facts: what the media and social feeds get wrong
- Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population-Adjusted Indirect Treatment Comparison (external link)
Diabetes, Obesity and Metabolism, 2026
Cited in Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study (external link)
Diabetes, Obesity and Metabolism, 2026
Cited in GLP-1 medications and depression: what the evidence shows, and what to watch
- Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Approach (external link)
Diabetes, Obesity and Metabolism, 2026
Cited in Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
- Diagnostic Evaluation of an Increased Risk of Developing Small Intestinal Bacterial Overgrowth Associated with GLP-1 Receptor Agonists and Dual GLP-1/GIP Receptor Agonists: A Global Retrospective Multicenter Cohort Analysis (external link)
Diagnostics, 2025
Cited in GLP-1 myths vs. facts: what the media and social feeds get wrong, Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- Glucagon-like peptide-1 receptor agonists increase the risk of residual gastric content and pulmonary aspiration on upper endoscopy: A meta-analysis (external link)
Digestive and Liver Disease, 2025
Cited in Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- Pharmacological treatment of polyendocrine metabolic ovarian syndrome in adults (external link)
Drug and Therapeutics Bulletin
Cited in How GLP-1 medications affect men vs. women: what the sex differences actually are, Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching
- GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis (external link)
Drugs
Cited in Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps
- Orforglipron: First Approval (external link)
Drugs, 2026
Cited in Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
- Mirror exposure in adolescents with anorexia nervosa: a feasibility study on body image disturbance and attentional bias (external link)
Eating and Weight Disorders
Cited in Body-image lag after weight loss vs. body dysmorphia: how to tell the difference
- Exploring moderators of mirror exposure on pre- to post changes in body image outcomes: Systematic review and meta-analysis (external link)
Eating Disorders
Cited in Body-image lag after weight loss vs. body dysmorphia: how to tell the difference
- Phenotype tailored lifestyle intervention on weight loss and cardiometabolic risk factors in adults with obesity: a single-centre, non-randomised, proof-of-concept study (external link)
eClinicalMedicine, 2023
Cited in Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results
- Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression (external link)
eClinicalMedicine, 2026
Cited in Stopping a GLP-1: tapering, weight regain, and restarting safely
- Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers (external link)
Endocrine, 2020
Cited in Why hydration matters on a GLP-1: effects on weight loss and side effects
- GLP-1 and Its Analogs: Does Sex Matter? (external link)
Endocrinology
Cited in GLP-1 super-responders (and non-responders): why weight loss varies so much, How GLP-1 medications affect men vs. women: what the sex differences actually are
- Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation (external link)
Endocrinology, 2010
Cited in The thyroid C-cell tumor warning: what it means and who it applies to
- Image Analyzer Study of the Skin in Patients With Morbid Obesity and Massive Weight Loss (external link)
Eplasty, 2015
Cited in Does loose skin throw off your DXA, BIA, or Seca body-composition results?
- Efficacy, Safety and Tolerability of Lisdexamfetamine Dimesylate Treatment Compared With Placebo in Adults With Binge-Eating Disorder: A Systematic Review and Meta-Analysis of Randomised Controlled Trials (external link)
European Eating Disorders Review
Cited in GLP-1 medications and ADHD: what to know if you have both
- Comparison of two nutritional protocols in body re-composition of resistance-trained participants (external link)
European Journal of Applied Physiology, 2026
Cited in Weight loss vs. body recomposition goals on a GLP-1
- Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis (external link)
European Journal of Clinical Nutrition, 2025
- Efficacy and safety of hydrolyzed collagen supplementation on skin health outcomes: a systematic literature review of randomized controlled trials (external link)
European Journal of Clinical Nutrition, 2026
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis (external link)
European Journal of Endocrinology
Cited in Hormone replacement therapy (HRT) and GLP-1 medications: an overview, HRT for men (testosterone) and GLP-1 medications: what the connection really is
- Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities (external link)
European Journal of Internal Medicine, 2014
Cited in What is suppression, satiation, and satiety on a GLP-1?
- Immediate pre-meal water ingestion decreases voluntary food intake in lean young males (external link)
European Journal of Nutrition, 2015
Cited in Why hydration matters on a GLP-1: effects on weight loss and side effects
- The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis (external link)
European Journal of Preventive Cardiology, 2023
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Specific collagen peptides increase adaptions of patellar tendon morphology following 14-weeks of high-load resistance training: A randomized-controlled trial (external link)
European Journal of Sport Science, 2023
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system (external link)
Expert Opinion on Drug Safety
Cited in Compounded GLP-1 dosing: vials and syringes vs. pre-filled pens, Pharmacy sources for GLP-1 medications: compounded, telehealth, and counterfeit risks, GLP-1 microdosing: what it means, why people do it, and what the evidence actually says, "Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you
- The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the FDA Adverse Event Reporting System (FAERS) (external link)
Expert Opinion on Drug Safety, 2023
Cited in Mood changes and anhedonia on a GLP-1: what the research shows
- Comparison of gelatin and low-molecular weight gelatin hydrolysate ingestion on hydroxyproline (Hyp), Pro-Hyp and Hyp-Gly concentrations in human blood (external link)
Food Chemistry, 2021
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Extraction and characterization of valuable compounds from chicken sternal cartilage: Type II collagen and chondroitin sulfate (external link)
Food Chemistry, 2024
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Analysis of Predictive Equations for Estimating Resting Energy Expenditure in a Large Cohort of Morbidly Obese Patients (external link)
Frontiers in Endocrinology, 2018
Cited in Do TDEE calculators still work after big weight loss on a GLP-1?
- Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists (external link)
Frontiers in Endocrinology, 2024
Cited in GLP-1 microdosing: what it means, why people do it, and what the evidence actually says, Can you boost GLP-1 naturally? How food and lifestyle compare to the medications
- Real-world semaglutide in obesity cohort: effectiveness, safety and persistence across sex, BMI, and prior GLP-1RA treatment (external link)
Frontiers in Endocrinology, 2026
Cited in Stopping a GLP-1: tapering, weight regain, and restarting safely
- Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study (external link)
Frontiers in Nutrition, 2025
Cited in Fiber on a GLP-1: how much you need, which type, and powder vs. capsules, Why are protein, fat, and carbohydrates important?, Electrolytes on a GLP-1: when plain water isn't enough, Constipation on a GLP-1: why it happens and how to manage it
- "You can't shoot another bullet until you've reloaded the gun": Coaches' perceptions, practices and experiences of deloading in strength and physique sports (external link)
Frontiers in Sports and Active Living, 2022
Cited in A beginner's resistance-training plan on a GLP-1: sets, reps, and progression
- Obesity Energetics: Body Weight Regulation and the Effects of Diet Composition (external link)
Gastroenterology, 2017
Cited in What a calorie deficit is, and how to find a healthy one for yourself on a GLP-1
- A Subphenotype of Obesity With Reduced Enteroendocrine Glucagon-Like Peptide 1 Synthesis and Enhanced Tirzepatide Response (external link)
Gastroenterology, 2026
Cited in Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results
- Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis (external link)
Gastrointestinal Endoscopy, 2025
Cited in Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- Interrelationships between growth hormone and sleep (external link)
Growth Hormone & IGF Research
Cited in Sleep quality on a GLP-1: why it matters, what changes, and the sleep apnea connection
- Lipase Supplementation before a High-Fat Meal Reduces Perceptions of Fullness in Healthy Subjects (external link)
Gut and Liver, 2015
Cited in Physician's Choice Digestive Enzymes & 60 Billion Probiotic: are they worth it on a GLP-1?
- Racial and ethnic disparities in GLP-1 prescriptions among veterans with obesity across direct and community care settings (external link)
Health Affairs Scholar, 2026
- Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review of Mechanisms, Evidence, and Prescription Guidance (external link)
Healthcare, 2026
Cited in Stopping a GLP-1: tapering, weight regain, and restarting safely, Talking to your doctor about stopping or tapering off treatment
- Missed Doses, Missed Opportunities: Readmission Due to GLP-1RA Interruption Inspires Algorithms to Improve Reinitiation of Therapy at Discharge (external link)
Hospital Pharmacy, 2025
Cited in Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration
- Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Psychological Well-Being and Depressive Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (external link)
Human Psychopharmacology, 2026
Cited in GLP-1 medications and depression: what the evidence shows, and what to watch
- Effects of collagen-based supplements on skin's hydration and elasticity: A systematic review and meta-analysis (external link)
Indian Journal of Dermatology, Venereology and Leprology, 2025
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the ECNP (external link)
International Clinical Psychopharmacology
Cited in Talking to a mental health provider about body image or disordered eating history before treatment, Body-image lag after weight loss vs. body dysmorphia: how to tell the difference
- Glucagon-like peptide-1 receptor agonist semaglutide through the lens of psychiatry: a systematic review of potential benefits and risks (external link)
International Clinical Psychopharmacology
Cited in GLP-1s and a history of disordered eating: what the evidence says about safety
- How many steps/day are enough? For adults (external link)
International Journal of Behavioral Nutrition and Physical Activity, 2011
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Switching between GLP-1 receptor agonists in clinical practice: Expert consensus and practical guidance (external link)
International Journal of Clinical Practice, 2021
Cited in Talking to your doctor about switching GLP-1 medications
- Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis (external link)
International Journal of Dermatology, 2021
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- The risk of eating disorders comorbid with attention-deficit/hyperactivity disorder: A systematic review and meta-analysis (external link)
International Journal of Eating Disorders
Cited in GLP-1 medications and ADHD: what to know if you have both
- Effects of GLP-1 Receptor Agonist Therapy on Eating Disorder Risk and Psychological Distress in Adults With Class 3 Obesity (external link)
International Journal of Eating Disorders, 2025
Cited in Anxiety around eating or body image emerging during GLP-1 treatment
- Effect of consumption of chicory inulin on bowel function in healthy subjects with constipation: a randomized, double-blind, placebo-controlled trial (external link)
International Journal of Food Sciences and Nutrition
Cited in Fiber on a GLP-1: how much you need, which type, and powder vs. capsules
- A randomized controlled trial on the efficacy and safety of a food ingredient, collagen hydrolysate, for improving joint comfort (external link)
International Journal of Food Sciences and Nutrition, 2009
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up, Joint pain on a GLP-1: why it usually gets better, why it sometimes gets worse first
- Restoring Satiety After GLP-1/GIP Pharmacotherapy: Metabolic Stability, Diet Quality, and the Gut Microbiota (external link)
International Journal of Molecular Sciences, 2026
Cited in What is suppression, satiation, and satiety on a GLP-1?
- Proteome-Level Autophagy-Lysosome Remodelling Marks Ageing in Human Dermal Fibroblasts and Nominates Hydroxytyrosol as a Candidate Nutraceutical (external link)
International Journal of Molecular Sciences, 2026
Cited in Loose skin after GLP-1 weight loss: what actually helps and what's hype
- Protein intake and lean body mass preservation during energy intake restriction in overweight older adults (external link)
International Journal of Obesity
Cited in High-protein meals and snacks when your appetite is low on a GLP-1
- What is the pipeline for future medications for obesity? (external link)
International Journal of Obesity
Cited in "Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you
- Adaptive thermogenesis in humans (external link)
International Journal of Obesity, 2010
Cited in Calories in, calories out: the energy balance behind a calorie deficit on a GLP-1
- Association between gastrointestinal phenotypes and weight gain in younger adults: a prospective 4-year cohort study (external link)
International Journal of Obesity, 2020
Cited in Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results
- Tissue losses and metabolic adaptations both contribute to the reduction in resting metabolic rate following weight loss (external link)
International Journal of Obesity, 2022
Cited in Calories in, calories out: the energy balance behind a calorie deficit on a GLP-1, Do TDEE calculators still work after big weight loss on a GLP-1?
- Cumulative effect of obesity phenotypes on body weight and body mass index (external link)
International Journal of Obesity, 2024
Cited in Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results
- Precision medicine for obesity: current evidence and insights for personalization of obesity pharmacotherapy (external link)
International Journal of Obesity, 2024
Cited in Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results
- Effects of Different Vitamin C-Enriched Collagen Derivatives on Collagen Synthesis (external link)
International Journal of Sport Nutrition and Exercise Metabolism, 2019
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Impact of 24-Hr Diet and Physical Activity Control on Short-Term Precision Error of Dual-Energy X-Ray Absorptiometry Physique Assessment (external link)
International Journal of Sport Nutrition and Exercise Metabolism, 2022
Cited in Reading your DXA results over time: tracking fat vs. lean mass on a GLP-1, DXA scans for tracking progress on a GLP-1: what they are, how they compare to BIA, and how to get one
- Collagen Supplementation Augments Strength Training-Induced Gains in Tendon Size and Rate of Force Development in Elite Female Master Field Hockey Athletes (external link)
International Journal of Sport Nutrition and Exercise Metabolism, 2025
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Comparison of predictive equations for resting metabolic rate in healthy nonobese and obese adults: a systematic review (external link)
J Am Diet Assoc, 2005
Cited in Do TDEE calculators still work after big weight loss on a GLP-1?
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial (external link)
JAMA
Cited in Liraglutide (Victoza and Saxenda): how the daily GLP-1 differs
- Longitudinal study of moderate weight change and sleep-disordered breathing (external link)
JAMA
Cited in CPAP as the weight comes off: managing sleep apnea on a GLP-1
- Effect of 1 week of sleep restriction on testosterone levels in young healthy men (external link)
JAMA
Cited in Sleep quality on a GLP-1: why it matters, what changes, and the sleep apnea connection
- Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial (external link)
JAMA Internal Medicine
Cited in Stopping a GLP-1: tapering, weight regain, and restarting safely
- Association of Step Volume and Intensity With All-Cause Mortality in Older Women (external link)
JAMA Internal Medicine, 2019
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Prospective Associations of Daily Step Counts and Intensity With Cancer and Cardiovascular Disease Incidence and Mortality and All-Cause Mortality (external link)
JAMA Internal Medicine, 2022
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases (external link)
JAMA Internal Medicine, 2022
- Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology: Post Hoc Analysis of the STEP 1, 2, 3, and 5 Trials (external link)
JAMA Internal Medicine, 2024
Cited in GLP-1 medications and depression: what the evidence shows, and what to watch
- Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases (external link)
JAMA Network Open
Cited in Pharmacy sources for GLP-1 medications: compounded, telehealth, and counterfeit risks, "Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you
- Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination Treatment: A Secondary Analysis of a Randomized Clinical Trial (external link)
JAMA Network Open
Cited in Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps
- Association of Daily Step Patterns With Mortality in US Adults (external link)
JAMA Network Open, 2023
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial (external link)
JAMA Psychiatry
Cited in Alcohol on a GLP-1: cravings, tolerance, and what actually changes
- Associations of Bariatric Surgery With Changes in Interpersonal Relationship Status: Results From 2 Swedish Cohort Studies (external link)
JAMA Surgery
Cited in Talking to your partner about body changes and intimacy during treatment
- Using Pedometers to Increase Physical Activity and Improve Health: A Systematic Review (external link)
JAMA, 2007
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial (external link)
JAMA, 2013
Cited in Joint pain on a GLP-1: why it usually gets better, why it sometimes gets worse first
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial (external link)
JAMA, 2021
Cited in Stretching your GLP-1 dose past 7 days: what drug levels and early studies actually show, Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found, Stopping a GLP-1: tapering, weight regain, and restarting safely, Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss (external link)
JAMA, 2023
Cited in Talking to your doctor about side effects that aren't improving, Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial (external link)
JAMA, 2024
Cited in What "maintenance dose" actually means and how it's decided, Stopping a GLP-1: tapering, weight regain, and restarting safely, Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found, Talking to your doctor about stopping or tapering off treatment, Tapering vs. staying on a maintenance dose for long-term use, Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found
- Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US (external link)
JAMA, 2025
- Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial (external link)
JCI Insight
Cited in Alcohol on a GLP-1: cravings, tolerance, and what actually changes
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®) (external link)
Journal of Affective Disorders
Cited in Getting mental health support while on a GLP-1: finding a therapist and the challenges to name
- High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial (external link)
Journal of Bone and Mineral Research
Cited in Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps
- Does Diet-Induced Weight Loss Lead to Bone Loss in Overweight or Obese Adults? A Systematic Review and Meta-Analysis of Clinical Trials (external link)
Journal of Bone and Mineral Research
Cited in Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps
- Boerhaave's syndrome associated with glucagon-like peptide-1 receptor agonist use: a case report (external link)
Journal of Cardiothoracic Surgery, 2026
Cited in Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration
- Indices of relative weight and obesity (external link)
Journal of Chronic Diseases, 1972
Cited in What obesity actually is: history, diagnosis, and why medicine calls it a chronic disease
- GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)? A systematic review (external link)
Journal of Clinical & Translational Endocrinology
Cited in GLP-1s and a history of disordered eating: what the evidence says about safety
- Reliability and Agreement of Various InBody Body Composition Analyzers as Compared to Dual-Energy X-Ray Absorptiometry in Healthy Men and Women (external link)
Journal of Clinical Densitometry, 2018
Cited in DXA scans for tracking progress on a GLP-1: what they are, how they compare to BIA, and how to get one, Does loose skin throw off your DXA, BIA, or Seca body-composition results?
- Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome (external link)
Journal of Clinical Endocrinology & Metabolism
Cited in Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching
- Approach to the Patient: Low Testosterone Concentrations in Men With Obesity (external link)
Journal of Clinical Endocrinology & Metabolism
Cited in HRT for men (testosterone) and GLP-1 medications: what the connection really is, Hormone replacement therapy (HRT) and GLP-1 medications: an overview, Men's health on a GLP-1: testosterone, fertility, muscle, and the things worth watching
- Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures (external link)
Journal of Clinical Endocrinology & Metabolism
Cited in Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps
- Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study (external link)
Journal of Clinical Endocrinology & Metabolism, 2016
Cited in Micronutrient gaps on a GLP-1: a labs-first guide, Supplements on a GLP-1 journey: what actually helps, and why food comes first
- Menopausal Hormone Therapy Is Associated With Reduced Total and Visceral Adiposity: The OsteoLaus Cohort (external link)
Journal of Clinical Endocrinology & Metabolism, 2018
Cited in HRT for women and GLP-1 medications: menopause, weight, and body composition, Hormone replacement therapy (HRT) and GLP-1 medications: an overview
- WHAM - A Prospective Study of Weight and Body Composition After Risk-Reducing Bilateral Salpingo-oophorectomy (external link)
Journal of Clinical Endocrinology & Metabolism, 2023
Cited in Hormone replacement therapy (HRT) and GLP-1 medications: an overview, HRT for women and GLP-1 medications: menopause, weight, and body composition
- Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide (external link)
Journal of Clinical Endocrinology & Metabolism, 2024
Cited in GLP-1 myths vs. facts: what the media and social feeds get wrong, Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- Approach to the Patient With Thyroid Nodules: Considering GLP-1 Receptor Agonists (external link)
Journal of Clinical Endocrinology & Metabolism, 2025
Cited in The thyroid C-cell tumor warning: what it means and who it applies to
- Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus (external link)
Journal of Clinical Medicine, 2022
Cited in Talking to your doctor about side effects that aren't improving
- Probiotics in Irritable Bowel Syndrome: An Umbrella Review of 27 Systematic Reviews on Methodological Quality and Certainty of Evidence (external link)
Journal of Clinical Medicine, 2026
Cited in Physician's Choice Digestive Enzymes & 60 Billion Probiotic: are they worth it on a GLP-1?
- Semaglutide Misuse in Atypical Anorexia Nervosa - A Case Report (external link)
Journal of Clinical Psychopharmacology, 2024
Cited in Anxiety around eating or body image emerging during GLP-1 treatment
- Comparison of GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and DPP-4 Inhibitors as an Add-On Drug to Insulin Combined With Oral Hypoglycemic Drugs: Umbrella Review (external link)
Journal of Diabetes Research, 2024
Cited in GLP-1s with insulin or sulfonylureas: understanding hypoglycemia risk
- Insulin delivery device technology 2012: where are we after 90 years? (external link)
Journal of Diabetes Science and Technology, 2012
Cited in The history of GLP-1 auto-injectors: benefits over vials, and auto-injectors vs. dial pens
- Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes (external link)
Journal of Diabetes Science and Technology, 2015
Cited in The history of GLP-1 auto-injectors: benefits over vials, and auto-injectors vs. dial pens
- Risk factors for Lipohypertrophy in People With Insulin-Treated Diabetes: A Systematic Meta-Analysis (external link)
Journal of Diabetes Science and Technology, 2025
Cited in Injection site reactions: what's normal and what to watch for
- GLP-1 Receptor Agonists: Encouraging Signals for Treating Alcohol Use Disorder (external link)
Journal of General Internal Medicine
Cited in Alcohol on a GLP-1: cravings, tolerance, and what actually changes
- Prescribing GLPs for Obesity Treatment for Adults at a University Based Health Maintenance Organization by Race, Ethnicity, and Socioeconomic Status (external link)
Journal of General Internal Medicine, 2025
- Effect of ginger in the treatment of nausea and vomiting compared with vitamin B6 and placebo during pregnancy: a meta-analysis (external link)
Journal of Maternal-Fetal & Neonatal Medicine, 2020
- Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription (external link)
Journal of Medical Internet Research
Cited in "Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you
- Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls (external link)
Journal of Medical Microbiology, 2009
Cited in Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis, GLP-1 myths vs. facts: what the media and social feeds get wrong
- National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss (external link)
Journal of Medical Toxicology
Cited in "Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you
- Can an Abnormal Gastric Emptying Study Be Normal? (external link)
Journal of Nuclear Medicine Technology, 2025
Cited in Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- Diet Quality and Micronutrient Intake among United States Adults Eligible for GLP-1 Receptor Agonist Antiobesity Medications: A Nationally Representative Analysis (external link)
Journal of Nutrition, 2026
Cited in Supplements on a GLP-1 journey: what actually helps, and why food comes first, Micronutrient gaps on a GLP-1: a labs-first guide
- Navigating Glucagon-Like Peptide Receptor Agonist Reinitiation Amid Access Barriers: An Adverse Drug Event Case Report (external link)
Journal of Pharmacy Practice, 2024
Cited in Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration
- The influence of lidocaine temperature on pain during subcutaneous injection (external link)
Journal of Plastic Surgery and Hand Surgery (Lundbom et al., 2016) — via PubMed
Cited in Pen types and injection technique across GLP-1 brands, Shot day routines: how the GLP-1 community builds a weekly injection ritual
- Complications following body contouring surgery after massive weight loss: a meta-analysis (external link)
Journal of Plastic, Reconstructive & Aesthetic Surgery, 2013
Cited in Loose skin after GLP-1 weight loss: what actually helps and what's hype
- Retrospective chart review on psychiatric manifestations of GLP-1 agonist usage (external link)
Journal of Psychiatric Research
Cited in GLP-1 medications and anxiety: what the evidence shows, and what to watch
- Effects of resistance training performed to repetition failure or non-failure on muscular strength and hypertrophy: A systematic review and meta-analysis (external link)
Journal of Sport and Health Science, 2022
Cited in A beginner's resistance-training plan on a GLP-1: sets, reps, and progression
- Strength and Hypertrophy Adaptations Between Low- vs. High-Load Resistance Training: A Systematic Review and Meta-analysis (external link)
Journal of Strength and Conditioning Research, 2017
Cited in A beginner's resistance-training plan on a GLP-1: sets, reps, and progression
- Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber (external link)
Journal of the Academy of Nutrition and Dietetics
Cited in Fiber on a GLP-1: how much you need, which type, and powder vs. capsules
- Relationship of Daily Step Counts to All-Cause Mortality and Cardiovascular Events (external link)
Journal of the American College of Cardiology, 2023
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients (external link)
Journal of the American College of Cardiology, 2025
Cited in Pancreatitis and GLP-1 medications: warning signs and when to seek emergency care, Kidney injury risk from dehydration on a GLP-1, Gallbladder disease and gallstones on a GLP-1, The thyroid C-cell tumor warning: what it means and who it applies to, The cardiovascular benefits of GLP-1 medications
- Administration errors of compounded semaglutide reported to a poison control center — Case series (external link)
Journal of the American Pharmacists Association
Cited in Reading an insulin syringe: units, mL, and mg for compounded GLP-1 doses, "Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you, Compounded GLP-1 dosing: vials and syringes vs. pre-filled pens
- Call to action for drug interactions between tirzepatide and heart failure guideline-directed medical therapy (external link)
Journal of the American Pharmacists Association, 2023
Cited in Why hydration matters on a GLP-1: effects on weight loss and side effects
- How much protein can the body use in a single meal for muscle-building? Implications for daily protein distribution (external link)
Journal of the International Society of Sports Nutrition
Cited in Protein quality: how to spot it on a nutrition label, and why it matters for muscle, "Your body can only use 30g of protein per meal": what the research actually says
- The impact of nutrition on tendon health and tendinopathy: a systematic review (external link)
Journal of the International Society of Sports Nutrition, 2022
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Segmental fat-free mass and lean soft mass: a comparative study with DXA, BIA and anthropometry (external link)
Journal of the International Society of Sports Nutrition, 2025
Cited in DXA scans for tracking progress on a GLP-1: what they are, how they compare to BIA, and how to get one, Does loose skin throw off your DXA, BIA, or Seca body-composition results?
- Dietary intake patterns and nutritional adequacy among adults with overweight or obesity treated with GLP-1 or dual GIP/GLP-1 receptor agonists — preliminary study (external link)
Journal of Translational Medicine, 2026
Cited in Hair loss on a GLP-1: what the evidence actually shows, Cronometer, What a calorie deficit is, and how to find a healthy one for yourself on a GLP-1, Why are protein, fat, and carbohydrates important?, Micronutrient gaps on a GLP-1: a labs-first guide, Fatigue and low energy during GLP-1 titration
- Could semaglutide be related to increasing the risk of developing a disordered eating? (external link)
L'Encephale, 2024
Cited in Anxiety around eating or body image emerging during GLP-1 treatment
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial (external link)
Lancet, 2021
Cited in GLP-1 super-responders (and non-responders): why weight loss varies so much
- Body Composition Optimization in the Era of GLP-1-Based Pharmacotherapy for Obesity Management (external link)
Lifestyle Medicine, 2026
Cited in Weight loss vs. body recomposition goals on a GLP-1, Body-image lag after weight loss vs. body dysmorphia: how to tell the difference, Does loose skin throw off your DXA, BIA, or Seca body-composition results?, Why strength training matters on a GLP-1, DXA scans for tracking progress on a GLP-1: what they are, how they compare to BIA, and how to get one, Common mistakes people make on GLP-1 medications — and how to avoid them
- GLP1 and GIP Receptor Agonists: Effects on the Gastrointestinal Tract and Management Strategies for Primary Care Physicians (external link)
Mayo Clinic Proceedings
- Semaglutide for the treatment of cognitive dysfunction in major depressive disorder: A randomized clinical trial (external link)
Med
Cited in Getting mental health support while on a GLP-1: finding a therapist and the challenges to name
- Maintenance of Lost Weight and Long-Term Management of Obesity (external link)
Medical Clinics of North America, 2018
Cited in Stopping a GLP-1: tapering, weight regain, and restarting safely
- New Frontiers in Nutritional and Therapeutic Interventions for Obesity Phenotypes (external link)
Medicina, 2025
Cited in Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results
- Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis (external link)
Medicine (Baltimore), 2023
Cited in GI side effects on a GLP-1: nausea, vomiting, diarrhea, and constipation, Constipation on a GLP-1: why it happens and how to manage it
- The Effect of Specific Bioactive Collagen Peptides on Tendon Remodeling during 15 wk of Lower Body Resistance Training (external link)
Medicine & Science in Sports & Exercise, 2023
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Cross-sectional analysis of the reliability and engagement metrics of YouTube videos on semaglutide for weight loss (external link)
Medicine, 2026
Cited in How to find and join a GLP-1 patient advocacy or support community
- Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use (external link)
Menopause, 2024
Cited in HRT for women and GLP-1 medications: menopause, weight, and body composition, Hormone replacement therapy (HRT) and GLP-1 medications: an overview
- Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials (external link)
Minerva Endocrinology, 2020
Cited in Pancreatitis and GLP-1 medications: warning signs and when to seek emergency care
- The role of intermittent fasting in modulating oxidative stress: a narrative review (external link)
Molecular Biology Reports, 2026
Cited in Loose skin after GLP-1 weight loss: what actually helps and what's hype
- Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial (external link)
Nature Medicine
Cited in CPAP as the weight comes off: managing sleep apnea on a GLP-1
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial (external link)
Nature Medicine, 2022
Cited in Do GLP-1 receptors "burn out"? What long-term use actually does
- Association of wearable device-measured vigorous intermittent lifestyle physical activity with mortality (external link)
Nature Medicine, 2022
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Association of semaglutide with risk of suicidal ideation in a real-world cohort (external link)
Nature Medicine, 2024
Cited in GLP-1 medications and depression: what the evidence shows, and what to watch, Mood changes and anhedonia on a GLP-1: what the research shows, GLP-1 myths vs. facts: what the media and social feeds get wrong
- Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial (external link)
Nature Medicine, 2024
- Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial (external link)
Nature Medicine, 2026
Cited in Tapering vs. staying on a maintenance dose for long-term use, Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found, Stopping a GLP-1: tapering, weight regain, and restarting safely
- An analysis on the role of glucagon-like peptide 1 receptor agonists in cognitive and mental health disorders (external link)
Nature Mental Health
Cited in GLP-1 medications and anxiety: what the evidence shows, and what to watch, Talking to a mental health provider about body image or disordered eating history before treatment
- Molecular connectomics reveals a glucagon-like peptide 1-sensitive neural circuit for satiety (external link)
Nature Metabolism, 2024
Cited in What is suppression, satiation, and satiety on a GLP-1?
- Association of GLP-1RA discontinuation and risk of depressive and anxiety disorders in people with type 2 diabetes: a cohort study (external link)
Nature Metabolism, 2026
Cited in GLP-1 medications and depression: what the evidence shows, and what to watch
- Causes and consequences of discontinuation of GLP1RAs or tirzepatide (external link)
Nature Reviews Endocrinology
Cited in Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration, Stopping a GLP-1: tapering, weight regain, and restarting safely
- Adolphe Quetelet (1796-1874): the average man and indices of obesity (external link)
Nephrology Dialysis Transplantation, 2008
Cited in What obesity actually is: history, diagnosis, and why medicine calls it a chronic disease
- Curbing the appetites and restoring the capacity for satisfaction: The impact of GLP-1 agonists on the reward circuitry (external link)
Neuroscience Applied
Cited in GLP-1 medications and ADHD: what to know if you have both
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity and Prediabetes) (external link)
New England Journal of Medicine
Cited in Liraglutide (Victoza and Saxenda): how the daily GLP-1 differs
- Aerobic or Resistance Exercise, or Both, in Dieting Obese Older Adults (external link)
New England Journal of Medicine
Cited in Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps, The 10,000 steps myth: where the number came from and what actually counts
- Long-term persistence of hormonal adaptations to weight loss (external link)
New England Journal of Medicine, 2011
Cited in "Taking a GLP-1 is cheating": where the myth comes from, and what the evidence says, What obesity actually is: history, diagnosis, and why medicine calls it a chronic disease, Talking to friends and family who are skeptical about GLP-1 use
- Conflicts of Interest for Patient-Advocacy Organizations (external link)
New England Journal of Medicine, 2017
Cited in The role of patient advocacy organizations in obesity treatment policy
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (external link)
New England Journal of Medicine, 2021
Cited in What to realistically expect on a GLP-1, GLP-1 super-responders (and non-responders): why weight loss varies so much, How GLP-1 medications work, in plain language, GLP-1 myths vs. facts: what the media and social feeds get wrong, Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found, When and why a prescriber might slow down your titration, Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps, How GLP-1 titration schedules work, Calories in, calories out: the energy balance behind a calorie deficit on a GLP-1, GLP-1 microdosing: what it means, why people do it, and what the evidence actually says, Fatigue and low energy during GLP-1 titration
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (external link)
New England Journal of Medicine, 2021
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (external link)
New England Journal of Medicine, 2022
- Tirzepatide Once Weekly for the Treatment of Obesity (external link)
New England Journal of Medicine, 2022
Cited in GLP-1 super-responders (and non-responders): why weight loss varies so much, Tirzepatide, Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps, How GLP-1 medications work, in plain language, Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found, What to realistically expect on a GLP-1, Does increasing your dose always mean more weight loss?
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF trial) (external link)
New England Journal of Medicine, 2023
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) (external link)
New England Journal of Medicine, 2023
Cited in The cardiovascular benefits of GLP-1 medications, GLP-1 myths vs. facts: what the media and social feeds get wrong, Do GLP-1 receptors "burn out"? What long-term use actually does, Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (external link)
New England Journal of Medicine, 2024
Cited in GLP-1 myths vs. facts: what the media and social feeds get wrong, Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found, The cardiovascular benefits of GLP-1 medications
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (external link)
New England Journal of Medicine, 2024
Cited in CPAP as the weight comes off: managing sleep apnea on a GLP-1, GLP-1 myths vs. facts: what the media and social feeds get wrong, Sleep quality on a GLP-1: why it matters, what changes, and the sleep apnea connection, Getting a sleep study: what to expect and how coverage works, Zepbound
- Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (external link)
New England Journal of Medicine, 2024
Cited in Joint pain on a GLP-1: why it usually gets better, why it sometimes gets worse first
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT) (external link)
New England Journal of Medicine, 2025
- Effectiveness of inulin intake on indicators of chronic constipation; a meta-analysis of controlled randomized clinical trials (external link)
Nutrición Hospitalaria
Cited in Fiber on a GLP-1: how much you need, which type, and powder vs. capsules
- Protein Distribution and Muscle-Related Outcomes: Does the Evidence Support the Concept? (external link)
Nutrients
Cited in "Your body can only use 30g of protein per meal": what the research actually says
- Prediction Equations Overestimate the Energy Requirements More for Obesity-Susceptible Individuals (external link)
Nutrients, 2017
Cited in Do TDEE calculators still work after big weight loss on a GLP-1?
- The Short-Chain Fatty Acid Acetate in Body Weight Control and Insulin Sensitivity (external link)
Nutrients, 2019
Cited in Can you boost GLP-1 naturally? How food and lifestyle compare to the medications
- Rehydration during Endurance Exercise: Challenges, Research, Options, Methods (external link)
Nutrients, 2021
Cited in Electrolytes on a GLP-1: when plain water isn't enough
- Effects of Oral Collagen for Skin Anti-Aging: A Systematic Review and Meta-Analysis (external link)
Nutrients, 2023
Cited in Loose skin after GLP-1 weight loss: what actually helps and what's hype, Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up, GLP-1 face: prevention, skincare, and what it actually signals
- Comparative Effectiveness of Nutritional Supplements in the Treatment of Knee Osteoarthritis: A Network Meta-Analysis (external link)
Nutrients, 2025
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up, Supplements on a GLP-1 journey: what actually helps, and why food comes first, Joint pain on a GLP-1: why it usually gets better, why it sometimes gets worse first
- Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (external link)
Nutrients, 2025
Cited in Should you get a personal trainer on a GLP-1?, Why strength training matters on a GLP-1
- Exploring Dietary Intake in Adults with Type 2 Diabetes Using GLP-1 Receptor Agonists: A Cross-Sectional Analysis (external link)
Nutrients, 2025
Cited in Cronometer, Micronutrient gaps on a GLP-1: a labs-first guide
- Hidden Malnutrition in the GLP-1 Era: Micronutrient Status, Protein Adequacy, and Lean Mass as Emerging Nutritional Considerations - A Narrative Review (external link)
Nutrients, 2026
- Nutrition-First Support for GLP-1 and Dual Incretin Therapy in Obesity: A Practical Framework for Dietary Management, Symptom Tolerability, and Long-Term Weight Maintenance (external link)
Nutrients, 2026
Cited in Stopping a GLP-1: tapering, weight regain, and restarting safely
- Diet induced thermogenesis (external link)
Nutrition & Metabolism, 2004
Cited in Calories in, calories out: the energy balance behind a calorie deficit on a GLP-1
- Metabolic adaptation is associated with less weight and fat mass loss in response to low-energy diets (external link)
Nutrition & Metabolism, 2021
Cited in Do TDEE calculators still work after big weight loss on a GLP-1?
- Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study (external link)
Nutrition Journal, 2016
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up, Joint pain on a GLP-1: why it usually gets better, why it sometimes gets worse first
- Nutrient-rich, high-quality, protein-containing dairy foods in combination with exercise in aging persons to mitigate sarcopenia (external link)
Nutrition Reviews
Cited in "Your body can only use 30g of protein per meal": what the research actually says
- Hyperuricemia, gout and obesity: should weight management be more of a focus in gout management? (external link)
Nutrition, Metabolism and Cardiovascular Diseases, 2026
Cited in Joint pain on a GLP-1: why it usually gets better, why it sometimes gets worse first
- Hair cortisol and adiposity in a population-based sample of 2,527 men and women aged 54 to 87 years (external link)
Obesity
Cited in Cortisol, stress, and weight on a GLP-1: what the connection really is
- Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Emptying (external link)
Obesity (Silver Spring, Md.), 2026
Cited in What is suppression, satiation, and satiety on a GLP-1?, Common GLP-1 side effects and how to manage them
- The internal circadian clock increases hunger and appetite in the evening independent of food intake and other behaviors (external link)
Obesity (Silver Spring)
Cited in High-protein meals and snacks when your appetite is low on a GLP-1
- Less frequent dosing of GLP-1 receptor agonists as a viable weight maintenance strategy (external link)
Obesity (Silver Spring)
Cited in Stretching your GLP-1 dose past 7 days: what drug levels and early studies actually show
- Reduced-Frequency GLP1 Therapy Maintains Weight, Body Composition, and Metabolic Syndrome Improvements: A Case Series (external link)
Obesity (Silver Spring)
Cited in Stretching your GLP-1 dose past 7 days: what drug levels and early studies actually show
- Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide (external link)
Obesity (Silver Spring), 2026
- Complications after body contouring surgery in post-bariatric patients: the importance of a stable weight close to normal (external link)
Obesity Facts, 2011
Cited in Loose skin after GLP-1 weight loss: what actually helps and what's hype
- Adaptive maintenance after incretin-induced weight loss: Moving beyond the continue-or-stop paradigm (external link)
Obesity Pillars
Cited in Stopping a GLP-1: tapering, weight regain, and restarting safely, Stretching your GLP-1 dose past 7 days: what drug levels and early studies actually show
- Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions (external link)
Obesity Pillars, 2025
- Dietary supplement considerations during glucagon-like Peptide-1 receptor agonist treatment: A narrative review (external link)
Obesity Pillars, 2025
Cited in Physician's Choice Digestive Enzymes & 60 Billion Probiotic: are they worth it on a GLP-1?, Why are protein, fat, and carbohydrates important?
- Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series (external link)
Obesity Pillars, 2026
Cited in Mood changes and anhedonia on a GLP-1: what the research shows
- Changes in food cravings, dietary quality, body composition, and dietary intake during GLP-1 receptor agonist therapy: The CRAVE study (external link)
Obesity Pillars, 2026
- Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework (external link)
Obesity Pillars, 2026
- Testosterone and obesity (external link)
Obesity Reviews
Cited in HRT for men (testosterone) and GLP-1 medications: what the connection really is
- Impact of weight bias and stigma on quality of care and outcomes for patients with obesity (external link)
Obesity Reviews, 2015
Cited in Weight stigma in healthcare settings: how to advocate for yourself with a dismissive provider
- Comparison of Histological Skin Changes After Massive Weight Loss in Post-bariatric and Non-bariatric Patients (external link)
Obesity Surgery, 2024
Cited in Loose skin after GLP-1 weight loss: what actually helps and what's hype, GLP-1 face: prevention, skincare, and what it actually signals
- Effect of calorie restriction on resting metabolic rate and spontaneous physical activity (external link)
Obesity, 2007
Cited in Calories in, calories out: the energy balance behind a calorie deficit on a GLP-1
- Efficacy of water preloading before main meals as a strategy for weight loss in primary care patients with obesity: RCT (external link)
Obesity, 2015
Cited in Why hydration matters on a GLP-1: effects on weight loss and side effects
- Persistent metabolic adaptation 6 years after "The Biggest Loser" competition (external link)
Obesity, 2016
Cited in Does increasing your dose always mean more weight loss?
- The effect of rate of weight loss on long-term weight regain in adults with overweight and obesity (external link)
Obesity, 2016
Cited in What a calorie deficit is, and how to find a healthy one for yourself on a GLP-1, Calories in, calories out: the energy balance behind a calorie deficit on a GLP-1
- Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers (external link)
Obesity, 2016
Cited in Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results, GLP-1 super-responders (and non-responders): why weight loss varies so much
- Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic (external link)
Obesity, 2021
Cited in Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results
- Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence (external link)
Obesity, 2026
- Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT (external link)
Obesity, 2026
Cited in GLP-1 medications and depression: what the evidence shows, and what to watch
- Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults: a meta-analysis (external link)
Open Access Journal of Sports Medicine, 2017
Cited in Supplements on a GLP-1 journey: what actually helps, and why food comes first
- The Intensive Diet and Exercise for Arthritis (IDEA) trial: 18-month radiographic and MRI outcomes (external link)
Osteoarthritis and Cartilage, 2015
Cited in Joint pain on a GLP-1: why it usually gets better, why it sometimes gets worse first
- Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis (external link)
Pancreatology, 2026
Cited in A new pancreas study on GLP-1 drugs: what it actually shows
- Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions - A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data (external link)
Pharmaceuticals (Basel), 2026
Cited in Injection site reactions: what's normal and what to watch for, Hair loss on a GLP-1: what the evidence actually shows
- The response of muscle protein synthesis following whole-body resistance exercise is greater following 40 g than 20 g of ingested whey protein (external link)
Physiological Reports
Cited in Protein quality: how to spot it on a nutrition label, and why it matters for muscle, "Your body can only use 30g of protein per meal": what the research actually says
- Barley β-glucan improves metabolic condition via short-chain fatty acids produced by gut microbial fermentation in high fat diet fed mice (external link)
PLoS One, 2018
Cited in Can you boost GLP-1 naturally? How food and lifestyle compare to the medications
- Are recent decreases in adult obesity trends in the United States encouraging or alarming? (external link)
Preventive Medicine
Cited in GLP-1s and a history of disordered eating: what the evidence says about safety
- Med14 phosphorylation shapes genomic response to GLP-1 agonists (external link)
Proceedings of the National Academy of Sciences, 2026
Cited in A new pancreas study on GLP-1 drugs: what it actually shows
- Dietary management of chronic constipation: a review of evidence-based strategies and clinical guidelines (external link)
Proceedings of the Nutrition Society
Cited in Fiber on a GLP-1: how much you need, which type, and powder vs. capsules
- Impact of menstrual cycle phase on endocrine effects of partial sleep restriction in healthy women (external link)
Psychoneuroendocrinology
Cited in Cortisol, stress, and weight on a GLP-1: what the connection really is
- Tolerance of rising dietary concentrations of esterified propoxylated glycerol (EPG) among human volunteers (external link)
Regulatory Toxicology and Pharmacology
Cited in EPG and the David protein bar controversy: what GLP-1 users should know
- Effects of combined metformin and semaglutide therapy on body weight, metabolic parameters, and reproductive outcomes in overweight/obese women with polycystic ovary syndrome: a prospective, randomized, controlled, open-label clinical trial (external link)
Reproductive Biology and Endocrinology
Cited in Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching
- Adverse Effects of GLP-1 Receptor Agonists (external link)
Review of Diabetic Studies, 2015
Cited in Kidney injury risk from dehydration on a GLP-1, GLP-1s with insulin or sulfonylureas: understanding hypoglycemia risk
- Beyond weight loss: Integrating GLP-1 RA therapies into psychological and behavioral care for obesity and binge eating disorder (external link)
Reviews in Endocrine & Metabolic Disorders
Cited in Body-image lag after weight loss vs. body dysmorphia: how to tell the difference
- Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series (external link)
SAGE Open Medical Case Reports, 2025
Cited in Should you get a personal trainer on a GLP-1?, Why strength training matters on a GLP-1, Joint pain on a GLP-1: why it usually gets better, why it sometimes gets worse first, Weight loss vs. body recomposition goals on a GLP-1, A beginner's resistance-training plan on a GLP-1: sets, reps, and progression, Body-image lag after weight loss vs. body dysmorphia: how to tell the difference
- Energy deficiency impairs resistance training gains in lean mass but not strength: A meta-analysis and meta-regression (external link)
Scandinavian Journal of Medicine & Science in Sports, 2022
Cited in A beginner's resistance-training plan on a GLP-1: sets, reps, and progression
- GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling (external link)
Science Progress, 2026
Cited in GLP-1 side effect timeline: what to expect at each stage, Hair loss on a GLP-1: what the evidence actually shows
- Role of nonexercise activity thermogenesis in resistance to fat gain in humans (external link)
Science, 1999
Cited in Calories in, calories out: the energy balance behind a calorie deficit on a GLP-1
- Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety (external link)
Science, 2025
Cited in Mood changes and anhedonia on a GLP-1: what the research shows, What is suppression, satiation, and satiety on a GLP-1?
- Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity (external link)
Scientific Reports
Cited in Alcohol on a GLP-1: cravings, tolerance, and what actually changes
- Comparison of whole body bone mineral density measurements between DXA and novel bioelectrical impedance analysis (external link)
Scientific Reports, 2024
Cited in Does loose skin throw off your DXA, BIA, or Seca body-composition results?, DXA scans for tracking progress on a GLP-1: what they are, how they compare to BIA, and how to get one
- Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology: a double-blind, placebo-controlled study (external link)
Skin Pharmacology and Physiology, 2013
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Oral Supplementation of Collagen Peptides Improves Skin Hydration by Increasing the Natural Moisturizing Factor Content in the Stratum Corneum: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (external link)
Skin Pharmacology and Physiology, 2021
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Metabolic consequences of sleep and sleep loss (external link)
Sleep Medicine
Cited in Sleep quality on a GLP-1: why it matters, what changes, and the sleep apnea connection
- Even with diet and exercise, Ozempic use reduces perceived effort and praiseworthiness of resulting weight loss (external link)
Social Science & Medicine
Cited in "Taking a GLP-1 is cheating": where the myth comes from, and what the evidence says, Talking to a new partner about being on a GLP-1 medication
- Effects of Acute Sleep Loss on Physical Performance: A Systematic and Meta-Analytical Review (external link)
Sports Medicine
Cited in Sleep quality on a GLP-1: why it matters, what changes, and the sleep apnea connection
- Human tendon adaptation in response to mechanical loading: a systematic review and meta-analysis of exercise intervention studies on healthy adults (external link)
Sports Medicine - Open, 2015
Cited in Joint pain on a GLP-1: why it usually gets better, why it sometimes gets worse first
- Deloading Practices in Strength and Physique Sports: A Cross-sectional Survey (external link)
Sports Medicine - Open, 2024
Cited in A beginner's resistance-training plan on a GLP-1: sets, reps, and progression
- How Many Steps/Day Are Enough? Preliminary pedometer indices for public health (external link)
Sports Medicine, 2004
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Effects of Supervised vs. Unsupervised Training Programs on Balance and Muscle Strength in Older Adults: A Systematic Review and Meta-Analysis (external link)
Sports Medicine, 2017
- Daily Step Count and All-Cause Mortality: A Dose-Response Meta-analysis of Prospective Cohort Studies (external link)
Sports Medicine, 2022
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Using Respiratory Gas Analyzers to Determine Resting Metabolic Rate in Adults: A Systematic Review of Validity Studies (external link)
Sports, 2025
Cited in Do TDEE calculators still work after big weight loss on a GLP-1?
- Effects of exercise training on glucocorticoid-induced muscle atrophy: Literature review (external link)
Steroids
Cited in Cortisol, stress, and weight on a GLP-1: what the connection really is
- The male hormone reset: how GLP-1RAs, lifestyle and testosterone transform obesity-linked problems (external link)
The Aging Male
Cited in Men's health on a GLP-1: testosterone, fertility, muscle, and the things worth watching
- Vitamin C-enriched gelatin supplementation before intermittent activity augments collagen synthesis (external link)
The American Journal of Clinical Nutrition, 2017
Cited in Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Predicting GLP-1 Discontinuation From Pharmacy Claims (external link)
The American Journal of Managed Care, 2026
Cited in Talking to your doctor about stopping or tapering off treatment, Stopping a GLP-1: tapering, weight regain, and restarting safely
- Effects of Collagen Supplements on Skin Aging: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (external link)
The American Journal of Medicine, 2025
Cited in Supplements on a GLP-1 journey: what actually helps, and why food comes first, Collagen peptides on a GLP-1: what the types actually mean, and which promises hold up
- Glucocorticoid-induced Fingerprints on Visceral Adipose Tissue Transcriptome and Epigenome (external link)
The Journal of Clinical Endocrinology & Metabolism
Cited in Cortisol, stress, and weight on a GLP-1: what the connection really is
- Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review (external link)
The Journal of Sexual Medicine
Cited in Men's health on a GLP-1: testosterone, fertility, muscle, and the things worth watching, HRT for men (testosterone) and GLP-1 medications: what the connection really is
- The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030 (external link)
The Lancet
Cited in Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching
- Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial (external link)
The Lancet Diabetes & Endocrinology, 2025
Cited in Does increasing your dose always mean more weight loss?, GLP-1 microdosing: what it means, why people do it, and what the evidence actually says
- Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts (external link)
The Lancet Public Health, 2022
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Daily steps and health outcomes in adults: a systematic review and dose-response meta-analysis (external link)
The Lancet Public Health, 2025
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4) (external link)
The Lancet, 2021
Cited in GLP-1s with insulin or sulfonylureas: understanding hypoglycemia risk
- Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial (external link)
The Lancet, 2025
- Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease (external link)
The Lancet, 2025
Cited in Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found
- Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+) (external link)
The Lancet, 2026
Cited in Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found
- Orforglipron vs oral semaglutide in type 2 diabetes (ACHIEVE-3): open-label randomised phase 3 trial (external link)
The Lancet, 2026
Cited in Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
- Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN) (external link)
The Lancet, 2026
Cited in Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found, Why some people stay on a lower maintenance dose, What "maintenance dose" actually means and how it's decided, Tapering vs. staying on a maintenance dose for long-term use, The history of GLP-1 medications: every approved drug, who made them, and what's coming next, Stopping a GLP-1: tapering, weight regain, and restarting safely
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome (external link)
The New England Journal of Medicine, 2015
Cited in Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (external link)
The New England Journal of Medicine, 2016
Cited in Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found, The cardiovascular benefits of GLP-1 medications
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (external link)
The New England Journal of Medicine, 2016
Cited in Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined (external link)
The New England Journal of Medicine, 2021
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (external link)
The New England Journal of Medicine, 2025
Cited in Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo, Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found, Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1) (external link)
The New England Journal of Medicine, 2025
Cited in Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (external link)
The New England Journal of Medicine, 2025
Cited in Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found, Every key GLP-1 clinical trial: what it tested, who paid for it, and what it found, Talking to your doctor about switching GLP-1 medications, Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo, How GLP-1 medications work, in plain language, Tirzepatide
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL) (external link)
The New England Journal of Medicine, 2025
Cited in Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
- Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4) (external link)
The New England Journal of Medicine, 2025
Cited in Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
- Tirzepatide for Obesity Treatment and Diabetes Prevention (external link)
The New England Journal of Medicine, 2025
Cited in Why some people stay on a lower maintenance dose, What "maintenance dose" actually means and how it's decided
- The association between glucagon-like peptide-1 receptor agonists and reported musculoskeletal adverse events: a systematic review and meta-analysis of randomized controlled trials (external link)
Therapeutic Advances in Musculoskeletal Disease
Cited in Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps
- Effects of bariatric surgery on hyperuricemia and gout: a systematic review of the literature (external link)
Updates in Surgery, 2024
Cited in Joint pain on a GLP-1: why it usually gets better, why it sometimes gets worse first
Clinical guidelines
- What clinicians should know about prescribing tirzepatide for sleep apnea (external link)
American Academy of Sleep Medicine
Cited in CPAP as the weight comes off: managing sleep apnea on a GLP-1
- Obstructive Sleep Apnea (external link)
American Academy of Sleep Medicine (Sleep Education)
Cited in Getting a sleep study: what to expect and how coverage works
- Sleep Study — what to expect from polysomnography and home sleep apnea testing (external link)
American Academy of Sleep Medicine (Sleep Education)
Cited in Getting a sleep study: what to expect and how coverage works
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026 (external link)
American Diabetes Association, 2026
Cited in GLP-1s with insulin or sulfonylureas: understanding hypoglycemia risk
- 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2026 (Recommendation 3.10) (external link)
American Diabetes Association, 2026
- Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (external link)
American Journal of Clinical Nutrition, 2025
- Consensus recommendations for gastric emptying scintigraphy: a joint report of the American Neurogastroenterology and Motility Society and the Society of Nuclear Medicine (external link)
American Journal of Gastroenterology, 2008
Cited in Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis
- Recognition of Obesity as a Disease (H-440.842) (external link)
American Medical Association House of Delegates
Cited in Obesity as a chronic disease vs. a lifestyle choice: why the framing matters
- Become a CNS: nutritionists and health professionals (external link)
American Nutrition Association / BCNS
Cited in Nutritionist vs. dietitian: what's the difference, and who to see on a GLP-1
- DCA License Search (California Board of Pharmacy license verification) (external link)
California Department of Consumer Affairs
Cited in How to verify a pharmacy is legitimate: BeSafeRx, NABP, and your state board
- Traveling Abroad with Medicine (external link)
CDC Travelers' Health
- Medicare GLP-1 Bridge (external link)
Centers for Medicare & Medicaid Services
Cited in Applying for a GLP-1 patient assistance program: step by step, How to contact your lawmakers about GLP-1 coverage: a step-by-step guide, The push to get Medicare to cover GLP-1 medications for obesity
- National Coverage Determination 240.4.1: Sleep Testing for Obstructive Sleep Apnea (OSA) (external link)
Centers for Medicare & Medicaid Services
Cited in Getting a sleep study: what to expect and how coverage works
- LCD L33718: Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea (external link)
Centers for Medicare & Medicaid Services
Cited in CPAP as the weight comes off: managing sleep apnea on a GLP-1
- Medicare GLP-1 Bridge: Information for Part D Plans (external link)
Centers for Medicare & Medicaid Services (CMS)
Cited in The push to get Medicare to cover GLP-1 medications for obesity
- 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults (external link)
Circulation, 2014
Cited in What a calorie deficit is, and how to find a healthy one for yourself on a GLP-1
- Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period (external link)
Clinical Gastroenterology and Hepatology, 2024
Cited in Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis, Shot day routines: how the GLP-1 community builds a weekly injection ritual
- Consumer Assistance Program (CAP Grants) (external link)
CMS
Cited in Escalation paths beyond your insurer: commissioners, ombudsmen, and external review
- RD Examination Eligibility Requirements (external link)
Commission on Dietetic Registration
Cited in Nutritionist vs. dietitian: what's the difference, and who to see on a GLP-1
- Graduate Degree Requirement for RDN Exam (external link)
Commission on Dietetic Registration
Cited in Nutritionist vs. dietitian: what's the difference, and who to see on a GLP-1
- H.R. 4231 — Treat and Reduce Obesity Act of 2025 (119th Congress) (external link)
Congress.gov, 2025
Cited in The Treat and Reduce Obesity Act (H.R. 4231 / S. 1973): what it is and why it matters, How to contact your lawmakers about GLP-1 coverage: a step-by-step guide
- S. 1973 — Treat and Reduce Obesity Act of 2025 (119th Congress) (external link)
Congress.gov, 2025
Cited in The Treat and Reduce Obesity Act (H.R. 4231 / S. 1973): what it is and why it matters, How to contact your lawmakers about GLP-1 coverage: a step-by-step guide
- Psyllium husk powder (OTC fiber therapy) - Drug Facts label (external link)
DailyMed (NLM)
Cited in Supplements on a GLP-1 journey: what actually helps, and why food comes first
- New injection recommendations for patients with diabetes (external link)
Diabetes & Metabolism (Frid et al., 2010) — via PubMed
Cited in Shot day routines: how the GLP-1 community builds a weekly injection ritual
- 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2025 (external link)
Diabetes Care (American Diabetes Association)
Cited in What the ADA guidelines say about GLP-1 medications — and what changed for type 1 diabetes in 2026
- 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026 (external link)
Diabetes Care (American Diabetes Association)
Cited in What the ADA guidelines say about GLP-1 medications — and what changed for type 1 diabetes in 2026
- 45 CFR 156.122(c): prescription drug exception process (external link)
Electronic Code of Federal Regulations
Cited in Advocating for coverage when you don't have a qualifying diagnosis code yet
- ZEPBOUND single-dose pen: Instructions for Use (external link)
Eli Lilly and Company (FDA-approved Instructions for Use), 2026
Cited in Injection site reactions: what's normal and what to watch for
- Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline (external link)
Endocrine Society, 2018
Cited in Hormone replacement therapy (HRT) and GLP-1 medications: an overview
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024 (external link)
European Medicines Agency, 2024
Cited in Mood changes and anhedonia on a GLP-1: what the research shows, GLP-1 myths vs. facts: what the media and social feeds get wrong, Getting mental health support while on a GLP-1: finding a therapist and the challenges to name, GLP-1 medications and depression: what the evidence shows, and what to watch
- Saxenda (liraglutide) injection — Prescribing Information, section 16 (storage) (external link)
FDA / DailyMed, 2026
Cited in Liraglutide (Victoza and Saxenda): how the daily GLP-1 differs, Pen types and injection technique across GLP-1 brands, Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration, Understanding your specific drug's dose ladder, What to do if you miss a GLP-1 dose, Storing and traveling with your GLP-1 medication, How GLP-1 titration schedules work
- Mounjaro (tirzepatide) injection — Prescribing Information, section 16.2 (storage) (external link)
FDA / DailyMed, 2026
Cited in Switching between diabetes and weight-management dosing of the same drug, Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration, Storing and traveling with your GLP-1 medication, Understanding your specific drug's dose ladder, What to do if you miss a GLP-1 dose
- Ozempic (semaglutide) injection — Prescribing Information, section 16 (storage) (external link)
FDA / DailyMed, 2026
Cited in Switching between diabetes and weight-management dosing of the same drug, What to do if you miss a GLP-1 dose, How compounded GLP-1 medications are made — and how that differs from the branded pens, Understanding your specific drug's dose ladder, Pen types and injection technique across GLP-1 brands, GLP-1s with insulin or sulfonylureas: understanding hypoglycemia risk, Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration, What happens if you accidentally take a double dose, Storing and traveling with your GLP-1 medication
- Trulicity (dulaglutide) — Prescribing Information and Instructions for Use (storage) (external link)
FDA / DailyMed, rev. August 2026
Cited in What to do if you miss a GLP-1 dose, Understanding your specific drug's dose ladder, Storing and traveling with your GLP-1 medication, Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration
- Foundayo (orforglipron) — Prescribing Information, section 16.2 (storage) (external link)
FDA / DailyMed, rev. August 2026
Cited in Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration, Understanding your specific drug's dose ladder, Storing and traveling with your GLP-1 medication, What to do if you miss a GLP-1 dose, Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
- Victoza (liraglutide) injection — Prescribing Information, section 16 (storage) (external link)
FDA / DailyMed, rev. November 2025
Cited in Liraglutide (Victoza and Saxenda): how the daily GLP-1 differs, Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration, Understanding your specific drug's dose ladder, Storing and traveling with your GLP-1 medication
- OZEMPIC (semaglutide) tablets and RYBELSUS (semaglutide) tablets: prescribing information (external link)
FDA label via DailyMed (label revised 1/2026)
Cited in Understanding your specific drug's dose ladder, Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide, Switching between diabetes and weight-management dosing of the same drug, What to do if you miss a GLP-1 dose, Myth: you must avoid certain foods on a GLP-1, Storing and traveling with your GLP-1 medication, Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration, Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
- ZEPBOUND (tirzepatide) prescribing information (external link)
FDA label via DailyMed, rev. August 2026
Cited in Fatigue and low energy during GLP-1 titration, Storing and traveling with your GLP-1 medication, The history of GLP-1 auto-injectors: benefits over vials, and auto-injectors vs. dial pens, Understanding insurance coverage for GLP-1 medications, HRT for women and GLP-1 medications: menopause, weight, and body composition, Injection site reactions: what's normal and what to watch for, Getting started: how to access GLP-1 medications, What happens if you accidentally take a double dose, Common mistakes people make on GLP-1 medications — and how to avoid them, Switching between diabetes and weight-management dosing of the same drug, Hair loss on a GLP-1: what the evidence actually shows, Understanding your specific drug's dose ladder, Shot day routines: how the GLP-1 community builds a weekly injection ritual, Pen types and injection technique across GLP-1 brands, When and why a prescriber might slow down your titration, Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching, Talking to your doctor about GLP-1 medications, Kidney injury risk from dehydration on a GLP-1, Pancreatitis and GLP-1 medications: warning signs and when to seek emergency care, Common GLP-1 side effects and how to manage them, GLP-1 side effect timeline: what to expect at each stage, Stretching your GLP-1 dose past 7 days: what drug levels and early studies actually show, Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration
- WEGOVY (semaglutide) injection prescribing information (external link)
FDA label via DailyMed, rev. June 2026
Cited in What happens if you accidentally take a double dose, Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching, Talking to your doctor about side effects that aren't improving, Why some people stay on a lower maintenance dose, The history of GLP-1 auto-injectors: benefits over vials, and auto-injectors vs. dial pens, How GLP-1 titration schedules work, Talking to your doctor about GLP-1 medications, Understanding insurance coverage for GLP-1 medications, Tapering vs. staying on a maintenance dose for long-term use, Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found, Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo, Alcohol on a GLP-1: cravings, tolerance, and what actually changes, Why hydration matters on a GLP-1: effects on weight loss and side effects, Pen types and injection technique across GLP-1 brands, Gallbladder disease and gallstones on a GLP-1, Stretching your GLP-1 dose past 7 days: what drug levels and early studies actually show, Myth: you must avoid certain foods on a GLP-1, Does increasing your dose always mean more weight loss?, When and why a prescriber might slow down your titration, Gastric emptying on a GLP-1: how much slower, how long it lasts, and what it means for gastroparesis, Switching between diabetes and weight-management dosing of the same drug, Storing and traveling with your GLP-1 medication, Talking to your doctor about stopping or tapering off treatment, Restarting a GLP-1 after a missed stretch: what each drug's label says about re-titration, Electrolytes on a GLP-1: when plain water isn't enough, What to do if you miss a GLP-1 dose, Do GLP-1 receptors "burn out"? What long-term use actually does, Shot day routines: how the GLP-1 community builds a weekly injection ritual, Advocating for coverage when you don't have a qualifying diagnosis code yet, Common mistakes people make on GLP-1 medications — and how to avoid them, Understanding your specific drug's dose ladder, GLP-1 medications and ADHD: what to know if you have both, Getting started: how to access GLP-1 medications, Stopping a GLP-1: tapering, weight regain, and restarting safely
- FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products (external link)
FDA MedWatch
Cited in How compounded GLP-1 medications are made — and how that differs from the branded pens
- List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the FD&C Act; Extension of Comment Period (external link)
Federal Register, 2026
Cited in The compounding pharmacy debate: patient access vs. safety regulation, FDA's proposal to keep compounded GLP-1s off the 503B bulks list — and how to comment
- The professions we regulate (external link)
HCPC
Cited in Nutritionist vs. dietitian: what's the difference, and who to see on a GLP-1
- Internal appeals (external link)
HealthCare.gov
Cited in How to write an effective insurance appeal letter, My insurance denied coverage. What now?, What a successful insurance appeal campaign looks like, Advocating for coverage when you don't have a qualifying diagnosis code yet
- External review — HealthCare.gov (external link)
HealthCare.gov (CMS), 2026
Cited in Escalation paths beyond your insurer: commissioners, ombudsmen, and external review, What a successful insurance appeal campaign looks like
- Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline (external link)
Journal of Clinical Sleep Medicine (AASM)
Cited in CPAP as the weight comes off: managing sleep apnea on a GLP-1
- Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults (external link)
Journal of Clinical Sleep Medicine (AASM)
Cited in CPAP as the weight comes off: managing sleep apnea on a GLP-1, Getting a sleep study: what to expect and how coverage works
- Position of the Academy of Nutrition and Dietetics: Health Implications of Dietary Fiber (external link)
Journal of the Academy of Nutrition and Dietetics
Cited in Fiber on a GLP-1: how much you need, which type, and powder vs. capsules
- Medical Nutrition Therapy Interventions Provided by Dietitians for Adult Overweight and Obesity Management: An Academy of Nutrition and Dietetics Evidence-Based Practice Guideline (external link)
Journal of the Academy of Nutrition and Dietetics, 2022
Cited in Nutritionist vs. dietitian: what's the difference, and who to see on a GLP-1
- 21 U.S.C. 353a — Pharmacy compounding (FD&C Act section 503A) (external link)
Legal Information Institute (Cornell Law School)
Cited in Talking to a pharmacist about compounded medications and sourcing
- 42 U.S. Code § 1395w-102 — Prescription drug benefits (definition of covered part D drug) (external link)
Legal Information Institute (Cornell), U.S. Code
Cited in The Treat and Reduce Obesity Act (H.R. 4231 / S. 1973): what it is and why it matters
- New Insulin Delivery Recommendations (external link)
Mayo Clinic Proceedings (Frid et al., 2016) — via PubMed
Cited in Shot day routines: how the GLP-1 community builds a weekly injection ritual, Pen types and injection technique across GLP-1 brands
- Medical nutrition therapy services (external link)
Medicare.gov
Cited in Nutritionist vs. dietitian: what's the difference, and who to see on a GLP-1
- American College of Sports Medicine position stand. Progression models in resistance training for healthy adults (external link)
Medicine & Science in Sports & Exercise, 2009
Cited in A beginner's resistance-training plan on a GLP-1: sets, reps, and progression
- The 2022 hormone therapy position statement of The North American Menopause Society (external link)
Menopause (The North American Menopause Society), 2022
Cited in Hormone replacement therapy (HRT) and GLP-1 medications: an overview, HRT for women and GLP-1 medications: menopause, weight, and body composition
- Semaglutide compounding guidance (external link)
Mississippi Board of Pharmacy
Cited in How compounded GLP-1 medications are made — and how that differs from the branded pens
- Find Safe Online Pharmacies: the .pharmacy domain and Safe Site Search Tool (external link)
National Association of Boards of Pharmacy
Cited in How to verify a pharmacy is legitimate: BeSafeRx, NABP, and your state board
- State Insurance Departments directory (external link)
National Association of Insurance Commissioners (NAIC)
- How Do I File a Complaint Against My Insurance Company? (external link)
National Association of Insurance Commissioners (NAIC)
Cited in Escalation paths beyond your insurer: commissioners, ombudsmen, and external review
- Dieting & Gallstones (external link)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Joint international consensus statement for ending stigma of obesity (external link)
Nature Medicine, 2020
Cited in What obesity actually is: history, diagnosis, and why medicine calls it a chronic disease
- Clinical practice guideline on diagnosis and treatment of hyponatraemia (external link)
Nephrology Dialysis Transplantation, 2014
Cited in Electrolytes on a GLP-1: when plain water isn't enough
- Vitamin D - Fact Sheet for Consumers (upper limits) (external link)
NIH Office of Dietary Supplements
- Calcium: Fact Sheet for Health Professionals (external link)
NIH Office of Dietary Supplements
Cited in Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps
- Iron - Fact Sheet for Consumers (external link)
NIH Office of Dietary Supplements
- Optimizing GLP-1 therapies for obesity and diabetes management (external link)
Obesity Pillars, 2025
- Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach (external link)
Obesity Pillars, 2026
Cited in Tapering vs. staying on a maintenance dose for long-term use, Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found, What "maintenance dose" actually means and how it's decided
- Physical Activity Guidelines for Americans, 2nd edition: Top 10 Things to Know (external link)
Office of Disease Prevention and Health Promotion (HHS)
Cited in Common mistakes people make on GLP-1 medications — and how to avoid them
- Preventing Obesity and Eating Disorders in Adolescents (external link)
Pediatrics, 2016
Cited in Talking to your kids about your GLP-1 treatment and body changes
- Tips for Submitting Effective Comments (external link)
Regulations.gov (eRulemaking Program)
Cited in Sharing your story: how patient testimonials influence coverage decisions and legislation
- Recommended Amount of Sleep for a Healthy Adult: A Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society (external link)
Sleep, 2015
Cited in Cortisol, stress, and weight on a GLP-1: what the connection really is
- Office of the Healthcare Advocate (external link)
State of Connecticut
Cited in Escalation paths beyond your insurer: commissioners, ombudsmen, and external review
- American Society for Metabolic and Bariatric Surgery Integrated Health Nutritional Guidelines for the Surgical Weight Loss Patient 2016 Update: Micronutrients (external link)
Surgery for Obesity and Related Diseases, 2017
- Multisociety clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period (external link)
Surgery for Obesity and Related Diseases, 2024
Cited in American Society for Metabolic and Bariatric Surgery (ASMBS)
- Definition and diagnostic criteria of clinical obesity (external link)
The Lancet Diabetes & Endocrinology, 2025
Cited in Obesity as a chronic disease vs. a lifestyle choice: why the framing matters, Common mistakes people make on GLP-1 medications — and how to avoid them, What obesity actually is: history, diagnosis, and why medicine calls it a chronic disease
- What Can I Bring? — Used Syringes (external link)
Transportation Security Administration
- What Can I Bring? — Unused Syringes (external link)
Transportation Security Administration
Cited in Storing and traveling with your GLP-1 medication, Safe sharps disposal for GLP-1 injectors
- Treatment of Low Blood Sugar (Hypoglycemia) — the 15-15 rule (external link)
U.S. Centers for Disease Control and Prevention
Cited in GLP-1s with insulin or sulfonylureas: understanding hypoglycemia risk
- 21 CFR 101.9 Nutrition labeling of food, paragraph (c)(7): protein (external link)
U.S. Code of Federal Regulations (Title 21)
Cited in Protein quality: how to spot it on a nutrition label, and why it matters for muscle
- USDA FoodData Central (SR Legacy): Greek yogurt plain lowfat (170903), cottage cheese 2% (172182), egg hard-boiled (173424) (external link)
U.S. Department of Agriculture, FoodData Central
Cited in High-protein meals and snacks when your appetite is low on a GLP-1
- Physical Activity Guidelines for Americans (2nd edition) (external link)
U.S. Department of Health and Human Services
Cited in A beginner's resistance-training plan on a GLP-1: sets, reps, and progression
- HHS Poverty Guidelines for 2026 (external link)
U.S. Department of Health and Human Services (ASPE)
Cited in Applying for a GLP-1 patient assistance program: step by step
- Physical Activity Guidelines for Americans, 2nd edition (external link)
U.S. Department of Health and Human Services, 2018
- Health Plans & Benefits: ERISA (external link)
U.S. Department of Labor
Cited in Escalation paths beyond your insurer: commissioners, ombudsmen, and external review
- What We Do (EBSA participant assistance) (external link)
U.S. Department of Labor, EBSA
Cited in Escalation paths beyond your insurer: commissioners, ombudsmen, and external review
- Technical Release 2011-02: Guidance on external review for group health plans and health insurance issuers (external link)
U.S. Department of Labor, EBSA
Cited in Escalation paths beyond your insurer: commissioners, ombudsmen, and external review
- Filing a Claim for Your Health Benefits (EBSA) (external link)
U.S. Department of Labor, EBSA
Cited in NAIC state insurance department directory, Escalation paths beyond your insurer: commissioners, ombudsmen, and external review
- Commenting on EPA Dockets (external link)
U.S. Environmental Protection Agency
Cited in The role of patient advocacy organizations in obesity treatment policy
- Safe Needle Disposal for Households (external link)
U.S. Environmental Protection Agency
- Enforcement Guidance: Disability-Related Inquiries and Medical Examinations of Employees under the ADA (external link)
U.S. Equal Employment Opportunity Commission
Cited in Talking to coworkers when they notice your weight loss
- Facts About the Americans with Disabilities Act (external link)
U.S. Equal Employment Opportunity Commission
Cited in Talking to coworkers when they notice your weight loss
- Best Way to Get Rid of Used Needles and Other Sharps (external link)
U.S. Food & Drug Administration
- DOs and DON'Ts of Proper Sharps Disposal (external link)
U.S. Food & Drug Administration
- Safely Using Sharps (Needles and Syringes) at Home, at Work and on Travel (external link)
U.S. Food & Drug Administration
- Sharps Disposal Containers (external link)
U.S. Food & Drug Administration
- FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain (external link)
U.S. Food and Drug Administration
Cited in Pharmacy sources for GLP-1 medications: compounded, telehealth, and counterfeit risks, How to verify a pharmacy is legitimate: BeSafeRx, NABP, and your state board, "Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you
- Pediatric Postmarketing Pharmacovigilance Review: Bydureon, Bydureon BCise and Byetta (exenatide) (external link)
U.S. Food and Drug Administration
Cited in The thyroid C-cell tumor warning: what it means and who it applies to, The history of GLP-1 medications: every approved drug, who made them, and what's coming next
- Agency Response Letter GRAS Notice No. GRN 000640 (esterified propoxylated glycerol) (external link)
U.S. Food and Drug Administration
Cited in EPG and the David protein bar controversy: what GLP-1 users should know
- Compounding and the FDA: Questions and Answers (external link)
U.S. Food and Drug Administration
Cited in Compounded GLP-1 dosing: vials and syringes vs. pre-filled pens, The compounding pharmacy debate: patient access vs. safety regulation
- Questions and Answers on Dietary Supplements (external link)
U.S. Food and Drug Administration
Cited in Supplements on a GLP-1 journey: what actually helps, and why food comes first
- BeSafeRx: Your Source for Online Pharmacy Information (external link)
U.S. Food and Drug Administration
Cited in Talking to a pharmacist about compounded medications and sourcing, How to verify a pharmacy is legitimate: BeSafeRx, NABP, and your state board, Pharmacy sources for GLP-1 medications: compounded, telehealth, and counterfeit risks
- FDA Approves First Medication for Obstructive Sleep Apnea (external link)
U.S. Food and Drug Administration
Cited in CPAP as the weight comes off: managing sleep apnea on a GLP-1, Men's health on a GLP-1: testosterone, fertility, muscle, and the things worth watching
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy (external link)
U.S. Food and Drug Administration
Cited in HRT for women and GLP-1 medications: menopause, weight, and body composition
- Step 3: Clinical Research — The Drug Development Process (external link)
U.S. Food and Drug Administration
- Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity (external link)
U.S. Food and Drug Administration
Cited in Getting mental health support while on a GLP-1: finding a therapist and the challenges to name
- Considering an Online Pharmacy? (BeSafeRx safe signs vs. warning signs) (external link)
U.S. Food and Drug Administration
Cited in How to verify a pharmacy is legitimate: BeSafeRx, NABP, and your state board
- FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (external link)
U.S. Food and Drug Administration
Cited in What happens if you accidentally take a double dose, Reading an insulin syringe: units, mL, and mg for compounded GLP-1 doses, GLP-1 microdosing: what it means, why people do it, and what the evidence actually says, Compounded GLP-1 dosing: vials and syringes vs. pre-filled pens, The history of GLP-1 auto-injectors: benefits over vials, and auto-injectors vs. dial pens
- FDA Approves Labeling Changes to Menopausal Hormone Therapy Products (external link)
U.S. Food and Drug Administration
Cited in HRT for women and GLP-1 medications: menopause, weight, and body composition
- FDA Drug Shortages: Liraglutide Injection (external link)
U.S. Food and Drug Administration
Cited in Liraglutide (Victoza and Saxenda): how the daily GLP-1 differs
- FDA warning letter to Gram Peptides (March 31, 2026) (external link)
U.S. Food and Drug Administration
Cited in "Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (external link)
U.S. Food and Drug Administration
Cited in FDA's proposal to keep compounded GLP-1s off the 503B bulks list — and how to comment, The compounding pharmacy debate: patient access vs. safety regulation, Liraglutide (Victoza and Saxenda): how the daily GLP-1 differs, Reading an insulin syringe: units, mL, and mg for compounded GLP-1 doses, Getting started: how to access GLP-1 medications, Pharmacy sources for GLP-1 medications: compounded, telehealth, and counterfeit risks, How compounded GLP-1 medications are made — and how that differs from the branded pens, Compounded GLP-1 dosing: vials and syringes vs. pre-filled pens
- Purple Book product details: Adlyxin (lixisenatide), BLA 208471 (external link)
U.S. Food and Drug Administration (Purple Book)
Cited in The history of GLP-1 medications: every approved drug, who made them, and what's coming next
- FDA approves weight management drug for patients aged 12 and older (external link)
U.S. Food and Drug Administration, 2020
Cited in Talking to your kids about your GLP-1 treatment and body changes
- Wegovy (semaglutide) injection, supplemental approval letter NDA 215256/S-005 (external link)
U.S. Food and Drug Administration, 2022
Cited in Talking to your kids about your GLP-1 treatment and body changes
- FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 RA Medications (external link)
U.S. Food and Drug Administration, 2026
Cited in GLP-1 medications and depression: what the evidence shows, and what to watch, Mood changes and anhedonia on a GLP-1: what the research shows, GLP-1 myths vs. facts: what the media and social feeds get wrong, GLP-1s and a history of disordered eating: what the evidence says about safety, GLP-1 medications and anxiety: what the evidence shows, and what to watch, Getting mental health support while on a GLP-1: finding a therapist and the challenges to name
- FDA approval letter: Foundayo (orforglipron) tablets, NDA 220934 (external link)
U.S. Food and Drug Administration, 2026
Cited in Foundayo
- H.R. 2415 (113th Congress) — Treat and Reduce Obesity Act of 2013, introduced in House (external link)
U.S. Government Publishing Office (govinfo)
Cited in The Treat and Reduce Obesity Act (H.R. 4231 / S. 1973): what it is and why it matters
- Find Your Representative (external link)
U.S. House of Representatives
Cited in How to contact your lawmakers about GLP-1 coverage: a step-by-step guide
- NIH: Clinical Trials and You — participant guide (informed consent, rights, what to ask) (external link)
U.S. National Institutes of Health
- ClinicalTrials.gov — U.S. registry and results database of clinical studies (external link)
U.S. National Library of Medicine / NIH
- Osteoporosis to Prevent Fractures: Screening (USPSTF recommendation, January 2025) (external link)
U.S. Preventive Services Task Force
Cited in Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps
- Contacting U.S. Senators (external link)
U.S. Senate
Cited in How to contact your lawmakers about GLP-1 coverage: a step-by-step guide
- Zepbound (tirzepatide) – Obstructive Sleep Apnea Only: prior authorization policy (external link)
UnitedHealthcare
Cited in CPAP as the weight comes off: managing sleep apnea on a GLP-1
- Contact elected officials (external link)
USA.gov
Cited in How to contact your lawmakers about GLP-1 coverage: a step-by-step guide
Reporting
- Changes to Novo Nordisk Patient Assistance Program (PAP) 2026 (external link)
340B Price Guide
Cited in Applying for a GLP-1 patient assistance program: step by step
- The American Diabetes Association Releases 'Standards of Care in Diabetes—2026' (external link)
American Diabetes Association (press release)
Cited in What the ADA guidelines say about GLP-1 medications — and what changed for type 1 diabetes in 2026
- Recognition of Obesity as a Disease (AMA Policy H-440.842) (external link)
American Medical Association, 2013
Cited in What obesity actually is: history, diagnosis, and why medicine calls it a chronic disease
- Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea (external link)
Apnimed
Cited in CPAP as the weight comes off: managing sleep apnea on a GLP-1
- Shotsy GLP-1 Tracker (App Store listing) (external link)
Apple App Store, accessed September 2026
Cited in Shotsy
- New Study Finds Metabolic and Bariatric Surgery After GLP-1 Treatment Significantly Boosts Weight Loss (external link)
ASMBS news release, May 2026
Cited in American Society for Metabolic and Bariatric Surgery (ASMBS)
- Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries (external link)
Centers for Medicare & Medicaid Services (CMS)
Cited in The push to get Medicare to cover GLP-1 medications for obesity
- Cigna Drug Coverage Policy IP0206: Weight Loss — Glucagon-Like Peptide-1 Agonists — Foundayo (external link)
Cigna coverage policy
Cited in Understanding insurance coverage for GLP-1 medications
- More people with type 1 diabetes are using GLP-1 drugs, study finds, despite limited evidence on safety or effectiveness (external link)
CNN, 2025
Cited in What the ADA guidelines say about GLP-1 medications — and what changed for type 1 diabetes in 2026
- DEXA Scan Cost in 2026: Body Composition and Bone Density (external link)
Composition ID (DEXA provider), 2026
Cited in Does loose skin throw off your DXA, BIA, or Seca body-composition results?, DXA scans for tracking progress on a GLP-1: what they are, how they compare to BIA, and how to get one
- Citizen-Centric Advocacy: The Untapped Power of Constituent Engagement (external link)
Congressional Management Foundation, 2017
Cited in Sharing your story: how patient testimonials influence coverage decisions and legislation, The role of patient advocacy organizations in obesity treatment policy, How to contact your lawmakers about GLP-1 coverage: a step-by-step guide
- Zepbound (tirzepatide) FDA Approval History (external link)
Drugs.com
Cited in Tirzepatide
- Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect (external link)
Eli Lilly and Company
Cited in LillyDirect vs. NovoCare: how manufacturer direct-pay actually works
- Zepbound Savings Card (external link)
Eli Lilly and Company
Cited in Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide
- Trulicity Savings Card (external link)
Eli Lilly and Company
Cited in Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide
- Mounjaro Savings Card (external link)
Eli Lilly and Company
Cited in Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide
- Zepbound savings: commercial insurance without Zepbound coverage (external link)
Eli Lilly and Company
Cited in Understanding insurance coverage for GLP-1 medications
- Foundayo (orforglipron) Coverage & Savings (external link)
Eli Lilly and Company
Cited in Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide, LillyDirect vs. NovoCare: how manufacturer direct-pay actually works
- Authentic Zepbound (tirzepatide) Shipped to You — LillyDirect (external link)
Eli Lilly and Company (LillyDirect)
Cited in Getting started: how to access GLP-1 medications, LillyDirect vs. NovoCare: how manufacturer direct-pay actually works, Why some people stay on a lower maintenance dose
- FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions (external link)
Eli Lilly and Company (PR Newswire)
Cited in The push to get Medicare to cover GLP-1 medications for obesity
- FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions (external link)
Eli Lilly and Company (press release)
Cited in The history of GLP-1 medications: every approved drug, who made them, and what's coming next, Foundayo, Switching from a GLP-1 injection to a pill to keep the weight off: what the first trial found, Getting started: how to access GLP-1 medications, Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes (external link)
Eli Lilly and Company (press release), August 28, 2026
- FDA approves Lilly's Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes (external link)
Eli Lilly and Company, 2022
Cited in Tirzepatide
- FDA approves Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity (external link)
Eli Lilly and Company, 2024
Cited in Tirzepatide
- Foundayo (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S. (external link)
Eli Lilly press release, April 9, 2026
Cited in Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo, Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide, LillyDirect vs. NovoCare: how manufacturer direct-pay actually works
- More than half of those who stop GLP-1s restart within a year (ENDO 2026 abstract) (external link)
Endocrine Society
Cited in Stopping a GLP-1: tapering, weight regain, and restarting safely
- 2027 Express Scripts National Preferred Formulary (abbreviated drug list) (external link)
Express Scripts
Cited in How to determine if your insurance formulary covers GLP-1 medications
- List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act (external link)
Federal Register (FDA), 2026
Cited in FDA's proposal to keep compounded GLP-1s off the 503B bulks list — and how to comment
- Warning Letter to Physician's Choice (JB7, LLC): unsubstantiated claims for coronavirus prevention and treatment (external link)
Federal Trade Commission
Cited in Physician's Choice Digestive Enzymes & 60 Billion Probiotic: are they worth it on a GLP-1?
- A dietitian breaks down the David protein bar lawsuit (external link)
Food Network (Healthy Eats)
Cited in EPG and the David protein bar controversy: what GLP-1 users should know
- How GLP-1 weight-loss drugs can mess with birth control and pregnancy, U.K. agency warns (external link)
Fortune
Cited in Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching
- The Science of the GLP-1 "Super Responders" (external link)
Goby (clinical explainer)
Cited in GLP-1 super-responders (and non-responders): why weight loss varies so much
- How 'Ozempic shaming' illuminates complexities of treating weight problems (external link)
Harvard Gazette
Cited in "Taking a GLP-1 is cheating": where the myth comes from, and what the evidence says
- GLP-1s may improve erectile dysfunction, testosterone levels for men (external link)
Healio
Cited in Men's health on a GLP-1: testosterone, fertility, muscle, and the things worth watching
- Mounjaro approved to reduce cardiovascular events in adults with diabetes (external link)
Healio, 2026
Cited in Tirzepatide
- Does health insurance cover GLP-1 medications for weight loss? (external link)
healthinsurance.org, 2026
- Hikma receives FDA approval and launches the generic version of Victoza, Liraglutide, in the US (external link)
Hikma Pharmaceuticals (press release)
Cited in Liraglutide (Victoza and Saxenda): how the daily GLP-1 differs
- 2025 Employer Health Benefits Survey (external link)
KFF
Cited in Talking to your employer about GLP-1 coverage, Obesity as a chronic disease vs. a lifestyle choice: why the framing matters, What to say when your employer's benefits team says no, Why GLP-1 access is uneven across income and race, How employer self-funded plans decide GLP-1 coverage, and how to make the case for adding it, How GLP-1 coverage mandates differ by state, Talking to your doctor about GLP-1 medications, How to determine if your insurance formulary covers GLP-1 medications
- KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use (external link)
KFF
Cited in The compounding pharmacy debate: patient access vs. safety regulation
- Claims Denials and Appeals in ACA Marketplace Plans in 2024 (external link)
KFF
Cited in What a successful insurance appeal campaign looks like, My insurance denied coverage. What now?, Escalation paths beyond your insurer: commissioners, ombudsmen, and external review
- What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid (external link)
KFF, 2026
Cited in The Treat and Reduce Obesity Act (H.R. 4231 / S. 1973): what it is and why it matters, CPAP as the weight comes off: managing sleep apnea on a GLP-1, The push to get Medicare to cover GLP-1 medications for obesity
- Medicaid Coverage of and Spending on GLP-1s (external link)
KFF, 2026
Cited in How to contact your lawmakers about GLP-1 coverage: a step-by-step guide, How GLP-1 coverage mandates differ by state
- How to Apply — Lilly Cares (external link)
Lilly Cares Foundation
Cited in Applying for a GLP-1 patient assistance program: step by step
- Study identifies patients with obesity most likely to benefit from GLP-1-based treatment (press release on the Gastroenterology study) (external link)
Mayo Clinic News Network, 2026
Cited in Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results
- GLP-1 Weight-Loss Drug Demonstration Begins July 2026 (external link)
Medicare Rights Center
Cited in The push to get Medicare to cover GLP-1 medications for obesity
- Employers are challenged to keep healthcare affordable as costs soar: survey results (external link)
Mercer
Cited in How employer self-funded plans decide GLP-1 coverage, and how to make the case for adding it
- About NASM (external link)
National Academy of Sports Medicine, 2026
- Understanding Weight Loss Medications (NASM continuing-education course) (external link)
National Academy of Sports Medicine, 2026
Cited in NASM (National Academy of Sports Medicine), How to find a personal trainer when you're on a GLP-1
- GLP-1 Medications & Eating Disorders (external link)
National Association of Anorexia Nervosa and Associated Disorders (ANAD)
Cited in GLP-1s and a history of disordered eating: what the evidence says about safety
- FDA ends compounding discretion for tirzepatide, maintains discretion for semaglutide (external link)
National Community Pharmacists Association
Cited in How compounded GLP-1 medications are made — and how that differs from the branded pens
- 2026 Legislative Session Calendar (updated March 23, 2026) (external link)
National Conference of State Legislatures
Cited in How to contact your lawmakers about GLP-1 coverage: a step-by-step guide
- Medicare GLP-1 Bridge Program: Eligibility, Costs, and Access (external link)
National Council on Aging (NCOA)
Cited in The push to get Medicare to cover GLP-1 medications for obesity
- Lawsuit over calories in David protein bars is dropped (external link)
NBC News, 2026
Cited in EPG and the David protein bar controversy: what GLP-1 users should know
- NCCPT Certified Personal Trainer exam information (external link)
NCCPT (ISSA), 2026
Cited in How to find a personal trainer when you're on a GLP-1
- Novo Nordisk clinical trials finder (external link)
Novo Nordisk
- Novo Nordisk's Ozempic pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US (external link)
Novo Nordisk
Cited in Getting started: how to access GLP-1 medications, Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide, Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo
- Novo Nordisk introduces NovoCare Pharmacy, lowering cost of all doses of FDA-approved Wegovy (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients (external link)
Novo Nordisk
Cited in LillyDirect vs. NovoCare: how manufacturer direct-pay actually works
- Gene technology ethics — how Novo Nordisk produces polypeptides (external link)
Novo Nordisk
Cited in How compounded GLP-1 medications are made — and how that differs from the branded pens
- Ozempic (semaglutide) Self-Pay — NovoCare Pharmacy (external link)
Novo Nordisk (NovoCare Pharmacy)
Cited in LillyDirect vs. NovoCare: how manufacturer direct-pay actually works, NovoCare
- Wegovy (semaglutide) Online Pharmacy — NovoCare (external link)
Novo Nordisk (NovoCare Pharmacy)
Cited in LillyDirect vs. NovoCare: how manufacturer direct-pay actually works
- Diabetes Savings Card Program — NovoCare (external link)
Novo Nordisk (NovoCare)
Cited in NovoCare, Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide
- Saxenda Savings Offer discontinuation notice (external link)
Novo Nordisk (NovoCare)
Cited in Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide
- Savings Offer Program for Wegovy — NovoCare (external link)
Novo Nordisk (NovoCare)
Cited in Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide, Getting started: how to access GLP-1 medications
- Ozempic pill and pen price guide (external link)
Novo Nordisk (NovoCare)
Cited in LillyDirect vs. NovoCare: how manufacturer direct-pay actually works, Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide
- Novo Nordisk Patient Assistance Program (PAP) — NovoCare (external link)
Novo Nordisk (NovoCare)
Cited in Applying for a GLP-1 patient assistance program: step by step, Getting started: how to access GLP-1 medications
- Novo Nordisk Patient Assistance Program Application (external link)
Novo Nordisk (NovoCare)
Cited in Applying for a GLP-1 patient assistance program: step by step
- Novo Nordisk Patient Assistance Program (PAP) Available Products (NNIPAP_11_01012026) (external link)
Novo Nordisk (NovoCare)
Cited in Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide, Applying for a GLP-1 patient assistance program: step by step
- FDA approves Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults (external link)
Novo Nordisk (press release)
Cited in Comparing the GLP-1 pills: Ozempic tablets (Rybelsus), the Wegovy pill, and Foundayo, Manufacturer savings cards for every branded GLP-1, including the new pills: a side-by-side guide, The history of GLP-1 medications: every approved drug, who made them, and what's coming next
- Wegovy savings offer and self-pay options (external link)
NovoCare (Novo Nordisk)
Cited in Advocating for coverage when you don't have a qualifying diagnosis code yet
- Novel ingredients in functional foods: how regulation and innovation intersect (David Protein / EPG) (external link)
Nutritional Outlook
Cited in EPG and the David protein bar controversy: what GLP-1 users should know
- Height and weight discrimination is prohibited in New York City starting November 26, 2023 (external link)
NYC Commission on Human Rights
Cited in What to say when your employer's benefits team says no
- ObesityCareProviders.com provider locator (external link)
Obesity Action Coalition
Cited in Obesity Action Coalition (official site), Weight stigma in healthcare settings: how to advocate for yourself with a dismissive provider
- Corporate Council (external link)
Obesity Action Coalition
- About the OAC (external link)
Obesity Action Coalition
Cited in How to find and join a GLP-1 patient advocacy or support community, Obesity Action Coalition (official site)
- ObesityWeek 2026 (external link)
ObesityWeek (The Obesity Society)
Cited in The Obesity Society
- Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients (external link)
Pharmaceutical Executive
Cited in LillyDirect vs. NovoCare: how manufacturer direct-pay actually works, Why some people stay on a lower maintenance dose
- Novo Nordisk Submits NDA to FDA for CagriSema (external link)
Pharmaceutical Executive
Cited in The history of GLP-1 medications: every approved drug, who made them, and what's coming next
- MyPhenome test: order page (external link)
Phenomix Sciences (company website), checked September 2026
Cited in Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results
- Phenomix Sciences Launches MyPhenome Test Directly to Patients to Help Guide Weight Loss Treatment Based on Biology (external link)
Phenomix Sciences press release (PR Newswire), June 16, 2026
Cited in Obesity phenotypes: why "hungry gut" vs "hungry brain" may change your GLP-1 results
- No, you don't need 10,000 steps a day (external link)
Popular Science
Cited in The 10,000 steps myth: where the number came from and what actually counts
- Physician's Choice 60 Billion Probiotic Review (external link)
ProbioticsGuide
Cited in Physician's Choice Digestive Enzymes & 60 Billion Probiotic: are they worth it on a GLP-1?
- Find a Therapist, Psychologist, Counselor (external link)
Psychology Today
Cited in Getting mental health support while on a GLP-1: finding a therapist and the challenges to name
- SafeNeedleDisposal.org — state and ZIP code disposal lookup (external link)
SafeNeedleDisposal.org (a NeedyMeds project)
- How do GLP-1 agonists affect gene expression? (external link)
Salk Institute news release, 2026
Cited in A new pancreas study on GLP-1 drugs: what it actually shows
- Free GLP-1 Tracker App for Shots, Side Effects, and Weight (external link)
Shotsy (developer site), accessed September 2026
Cited in Shotsy
- Weight-loss drug coverage for Illinois state workers could cost hundreds of millions (external link)
St. Louis Public Radio / WBEZ
- Step Therapy Legislation by State (external link)
Step Therapy coalition (steptherapy.com)
- Teva Announces Launch of Authorized Generic of Victoza (liraglutide injection 1.8mg) in the United States (external link)
Teva Pharmaceuticals (press release)
Cited in Liraglutide (Victoza and Saxenda): how the daily GLP-1 differs
- Teva Announces FDA Approval and Launch of Generic Saxenda (liraglutide injection), First Generic GLP-1 Indicated for Weight Loss (external link)
Teva Pharmaceuticals (press release)
Cited in Liraglutide (Victoza and Saxenda): how the daily GLP-1 differs
- Family Guide to Recovery (external link)
The Emily Program
Cited in Talking to family members with a history of disordered eating about your treatment
- About The Obesity Society (external link)
The Obesity Society
Cited in The Obesity Society
- MHRA urges women taking weight-loss drugs to use effective contraception (external link)
The Pharmaceutical Journal
Cited in Women's health on a GLP-1: birth control, pregnancy, PCOS, bone, and the things worth watching
- Use of weight loss 'wonder drugs' has doubled. The Salk Institute is studying how far their benefits can go (external link)
Times of San Diego, 2026
Cited in A new pancreas study on GLP-1 drugs: what it actually shows
- Ready, Set, Dietetic: Dietitian Licensure Compact (external link)
Today's Dietitian
Cited in Nutritionist vs. dietitian: what's the difference, and who to see on a GLP-1
- Ozempic and ADHD: Does Semaglutide Interact With ADHD Medications? (external link)
TrimRx (clinical explainer)
Cited in GLP-1 medications and ADHD: what to know if you have both
- Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies (interim staff report) (external link)
U.S. Federal Trade Commission
Cited in How to determine if your insurance formulary covers GLP-1 medications
- Three CortiSlim Defendants to Give Up $4.5 Million in Cash and Other Assets (FTC enforcement action against cortisol weight-loss supplements) (external link)
U.S. Federal Trade Commission
Cited in Cortisol, stress, and weight on a GLP-1: what the connection really is
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (external link)
U.S. Food & Drug Administration
Cited in Talking to a pharmacist about compounded medications and sourcing, "Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you, LillyDirect vs. NovoCare: how manufacturer direct-pay actually works, How compounded GLP-1 medications are made — and how that differs from the branded pens, The compounding pharmacy debate: patient access vs. safety regulation, GLP-1 myths vs. facts: what the media and social feeds get wrong, Pharmacy sources for GLP-1 medications: compounded, telehealth, and counterfeit risks
- FDA Approves New Medication for Chronic Weight Management (Zepbound) (external link)
U.S. Food and Drug Administration, 2023
Cited in Tirzepatide
- Mounjaro (tirzepatide) FDA approval letter, supplement 215866Orig1s039 (pediatric type 2 diabetes) (external link)
U.S. Food and Drug Administration, 2025
Cited in Tirzepatide
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (external link)
U.S. Food and Drug Administration, 2026
Cited in The compounding pharmacy debate: patient access vs. safety regulation, FDA's proposal to keep compounded GLP-1s off the 503B bulks list — and how to comment
- What to Eat on GLP-1s: Best Foods & What to Avoid, According to a Dietitian (external link)
U.S. News & World Report
- UltiCare U-100 Insulin Syringes (external link)
UltiMed, Inc. (syringe manufacturer)
Cited in Reading an insulin syringe: units, mL, and mg for compounded GLP-1 doses
- Discontinuation of Bydureon BCise and Byetta (external link)
UnitedHealthcare provider notice
Cited in The history of GLP-1 medications: every approved drug, who made them, and what's coming next
- GLP-1 exposure calls to Connecticut Poison Control triple over 2 years (external link)
WFSB
Cited in "Research peptides" and GLP-1 medications: what they are, and what the label doesn't tell you
Community experience
- Statement from the Alliance for Pharmacy Compounding on FDA Proposed Rule Regarding 503B Bulks List (external link)
Alliance for Pharmacy Compounding
Cited in The compounding pharmacy debate: patient access vs. safety regulation
- NeedyMeds (external link)
NeedyMeds
Cited in Applying for a GLP-1 patient assistance program: step by step
- Our position on illicit compounding of semaglutide (external link)
Novo Nordisk
Cited in The compounding pharmacy debate: patient access vs. safety regulation
- Changes are Coming: Medicare Access to GLP-1 Medications (external link)
Obesity Action Coalition
Cited in The push to get Medicare to cover GLP-1 medications for obesity
- Treat and Reduce Obesity Act (TROA) — Obesity Action Coalition (external link)
Obesity Action Coalition, 2026
Cited in How to contact your lawmakers about GLP-1 coverage: a step-by-step guide, The Treat and Reduce Obesity Act (H.R. 4231 / S. 1973): what it is and why it matters
- 60 Billion Probiotic product page (external link)
Physician's Choice
Cited in Physician's Choice Digestive Enzymes & 60 Billion Probiotic: are they worth it on a GLP-1?
- Quality Standards & Testing (external link)
Physician's Choice
Cited in Physician's Choice Digestive Enzymes & 60 Billion Probiotic: are they worth it on a GLP-1?
- Digestive Enzymes product page (external link)
Physician's Choice
Cited in Physician's Choice Digestive Enzymes & 60 Billion Probiotic: are they worth it on a GLP-1?
- RxAssist — Patient Assistance Program Center (external link)
RxAssist
Cited in Applying for a GLP-1 patient assistance program: step by step